

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Improvement of perioperative care of the elderly patient (PeriAge): protocol of a controlled feasibility study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-031837
Article Type:	Protocol
Date Submitted by the Author:	21-May-2019
Complete List of Authors:	<p>Leberherz, Lisa; University Medical Center Hamburg-Eppendorf, Department of Medical Psychology  Olotu, Cynthia; University Medical Center Hamburg-Eppendorf, Department of Anaesthesiology  Härter, Martin; University Medical Center Hamburg-Eppendorf, Department of Medical Psychology  Mende, Anna; University Medical Center Hamburg-Eppendorf, Department of Anaesthesiology  Plümer, Lili; University Medical Center Hamburg-Eppendorf, Department of Anaesthesiology  Goetz, Alwin E; University Medical Center Hamburg-Eppendorf, Department of Anaesthesiology  Zöllner, Christian; University Medical Center Hamburg-Eppendorf, Department of Anaesthesiology  Kriston, Levente ; University Medical Center Hamburg-Eppendorf, Germany, Medical Psychology  Kiefmann, Rainer; University Medical Center Hamburg-Eppendorf, Department of Anaesthesiology</p>
Keywords:	feasibility, perioperative care, geriatric anaesthesia, anaesthesiology, post-operative complications, patient-reported outcomes

SCHOLARONE™  
Manuscripts

## Improvement of perioperative care of the elderly patient (PeriAge): protocol of a controlled feasibility study

Cynthia Olotu<sup>\*1</sup>, Lisa Lebherz<sup>\*2</sup>, Martin Härter<sup>2</sup>, Anna Mende<sup>1</sup>, Lili Plümer<sup>1</sup>, Alwin E Goetz<sup>1</sup>, Christian Zöllner<sup>1</sup>, Levente Kriston<sup>†2</sup>, Rainer Kiefmann<sup>†1</sup>

<sup>1</sup>Department of Anaesthesiology, University Medical Centre Hamburg-Eppendorf (UKE), Martinistraße 52, 20246 Hamburg, Germany.

<sup>2</sup>Department of Medical Psychology, University Medical Centre Hamburg-Eppendorf (UKE), Martinistraße 52, 20246 Hamburg, Germany.

\* CO and LL contributed equally to this paper

† LK and RK contributed equally to this paper

Email addresses:

Cynthia Olotu (CO)	c.olotu@uke.de
Lisa Lebherz (LL)	l.lebherz@uke.de
Martin Härter (MH)	m.haerter@uke.de
Anna Mende (AM)	a.bader@uke.de
Lili Plümer (LP)	l.pluemer@uke.de
Alwin E. Goetz (AEG)	agoetz@uke.de
Christian Zöllner (CZ)	c.zoellner@uke.de
Levente Kriston (LK)	l.kriston@uke.de
Rainer Kiefmann (RK)	r.kiefmann@uke.de

Corresponding author:

Lisa Lebherz, MSc.  
Department of Medical Psychology  
University Medical Centre Hamburg-Eppendorf (UKE)  
Martinistraße 52  
20246 Hamburg, Germany  
Email: l.lebherz@uke.de  
Phone: +49 (0)40 7410 57313

Date: 21.05.2019

Study start: 01.11.2017 (after study registration; start of the intervention phase, thus the “experimental condition” was 01.03.2019)

Protocol Version: 1

Word Count: 3465 words (excluding title page, abstract, tables, figures, author’s contributions, and references)

## ABSTRACT

**Introduction** Geriatric patients have a pronounced risk to suffer from postoperative complications. While effective and risk-specific pre- and intraoperative measures have been well studied in controlled research settings, they are rarely found in routine healthcare. This study aims (1) to implement a multicomponent pre- and intraoperative intervention for elderly patients and investigate its feasibility and (2) to assess the effectiveness of the intervention in routine healthcare.

**Methods and analysis** Feasibility and effectiveness of the intervention will be investigated in a monocentric, prospective, non-randomised, controlled trial. Data will successively be collected from control, implementation, and intervention group. Patients aged above 64 with impending surgery minimum 5 days after a premedication appointment will be included. A sample size of 240, n=80 per group, is planned. Assessments will take place at inclusion and 2, 30, and 180 days after surgery. Analyses are performed using a mixed-methods approach. The effectiveness will be assessed using mixed segmented regressions. The primary endpoint is functional status. Secondary endpoints include cognitive performance, health-related quality of life, length of inpatient stay and occurrence of postoperative complications. Feasibility will be assessed (a) through qualitative semi-structured interviews with clinical staff and patients and (b) quantitative analyses of the data quality, focussing on practicability, acceptance, adoption, and fidelity to protocol.

**Ethics and dissemination** The study will be carried out in accordance with the Helsinki Declaration of the World Medical Association and to principles of good scientific practice. The Ethics Committee of the Medical Association Hamburg, Germany approved the protocol (study ID: PV5596). Results will be disseminated in scientific journals and presentations at healthcare conferences.

**Trial registration** ClinicalTrials.gov Identifier: NCT03325413.

**Keywords** feasibility, perioperative care, elderly, geriatric anaesthesia, anaesthesiology, post-operative complications, complex interventions, instrumental activities of daily life, quality of life, patient-reported outcomes, process evaluation.

### Strengths and limitations of this study

- |   |   |
|---|---|
| + | Effectiveness AND feasibility evaluation of a multicomponent pre- and intraoperative intervention under real-life circumstances for a variety of surgeries and with few inclusion restrictions. |
| + | High patient relevance due to the use of a wide range of patient-reported outcome measures and long term follow-up  |
| + | Capturing multidisciplinary experience from anaesthetists, medical assistants, nurses, and patients.  |
| - | Difficulties to implement and control for all intervention components adequately due to real-life circumstances.  |
| - | Risk of selection and attrition bias due to the non-randomized design and selective dropout.  |

## INTRODUCTION

In Germany, every second inpatient surgical procedure is performed on patients aged 65 years and above.<sup>1</sup> This cohort has an elevated risk to suffer from a range of postoperative complications (POCs).<sup>2-6</sup> These include postoperative delirium (POD), pulmonary infection, cardiovascular events and an overall higher rate of postoperative morbidity, consequentially extended hospitalisations, and mortality, but also long-term general decline of health, cognition, functional status, and quality of life after surgery.<sup>7-11</sup> Further, immediate POCs can result in and amplify long-term decline of health and long-term loss of functional independence and quality of life. The most common patient-related risk factors are a reduced functional status, (i.a. sensory and cognitive impairment, poor physical fitness and mobility, malnutrition, polypharmacy, and multi-morbidity).<sup>12-15</sup> Treatment-associated risk factors include excessive fasting prior to surgery, dehydration, disorientation, disturbed sleep-wake-cycle, potential-inadequate medication, anxiety, mental overload and -stress, pain, hypothermia, loss of sensory orientation during in-patient stay,<sup>16</sup> and high invasiveness of the anaesthetic procedures and surgery (see figure 1).

### [FIGURE 1]

In order to reduce POCs and generally improve clinical outcomes in elderly patients, it is important to detect patient-related risk factors prior to surgery and implement appropriate prophylactic measures. Accordingly, risk-specific prehabilitative interventions need to find their way into routine healthcare<sup>12</sup>. Evidence is consistent, that preoperative prehabilitative measures can reduce the postoperative risk suffering POCs for elderly patients, and hence improve long-term functional status. Protective measures include countering malnutrition,<sup>17,18</sup> poor physical fitness,<sup>19,20</sup> and enhancing breathing exercise techniques,<sup>21</sup> as well as reducing potentially inappropriate or multi-medication.<sup>22,23</sup> Handling of preoperative fasting is another problematic aspect of perioperative care. While guidelines support that 6 hours of preoperative fasting are sufficient in most cases, this is hardly met in clinical practice.<sup>24,25</sup> Recent studies, however, point out the protective effect of preoperative carbohydrate intake and hence glucose reserve on the postoperative outcome, especially in vulnerable patients.<sup>26</sup> Further risk factors for less favourable postoperative outcomes are anxiety and psychological and mental stress. While the necessity of an inpatient surgery alone provokes a stress reaction, so does the entire medical procedure, from preanaesthetic evaluation to inpatient discharge. The unfamiliar environment and the uncertainty of the outcome can amplify anxiety and stress. This holds particularly true for potentially vulnerable patient groups, as is the geriatric cohort. Stress is well established to negatively impact somatic and mental health outcomes.<sup>27</sup> However, loss of orientation and high levels of stress can be reduced by marginal changes in routine preoperative procedures. Patients can be re-oriented by retaining glasses and hearing aids up to the anaesthetic induction, and by reducing mental

1  
2  
3 stress and overload. This can be done by ensuring that the patient understands the procedures for  
4 surgery and therapy and by encouraging the presence and involvement of relatives,<sup>28</sup> which in turn  
5 may lead to a higher preservation of preoperative self-reliance and health-related quality of life.<sup>29</sup>  
6 While the risk of suffering somatic POCs is increased in patients, who have blood deficiency states and  
7 undergo sanguineous surgery, this risk can be reduced by individualised iron substitution.<sup>30-33</sup>  
8  
9

10  
11  
12 Further, the risk of different intraoperative procedures should be taken into consideration. It is  
13 recommended to monitor the depth of anaesthesia using e.g. bispectral index (BIS) analysis, as deep  
14 anaesthesia is associated with a higher incidence of postoperative delirium.<sup>34</sup> Postoperative pain is a  
15 predisposing factor for POCs.<sup>35</sup> To enable sufficient postoperative, opioid-saving analgesia, the use of  
16 catheter-assisted regional anaesthesia is preferable for elderly patients.<sup>32,36</sup>  
17  
18  
19

20  
21 While these risk factors are well studied and several intervention components have been shown to  
22 reduce complication rates in controlled research settings,<sup>37-39</sup> many effective intervention components  
23 are not used in routine care,<sup>40,41</sup> as both an extensive preoperative risk assessment and the  
24 administration of pre- and intraoperative measures are time-consuming and costly.  
25  
26  
27

28  
29 To improve the geriatric patient's postoperative safety and health, the preanaesthetic evaluation  
30 needs to be updated to the current state of research of risk- and preventive factors. Feasibility and  
31 benefit of an extended preanaesthetic evaluation and the ensuing administration of corresponding  
32 prophylactic interventions need to be demonstrated, in that it is possible to improve the pre- and  
33 intraoperative care of geriatric patients with feasible effort, leading to an overall reduction in long-  
34 term physical and cognitive complications as well as a reduced hospitalisation period.  
35  
36  
37

38  
39 **Objectives** In this study, a demand- and risk-based intervention (called PeriAge-intervention) is  
40 developed and implemented into routine healthcare.  
41  
42

43  
44 Objective (1) is to assess and provide first evidence of the effectiveness of the PeriAge- intervention,  
45 improving the postoperative outcome of a sample of elderly patients at a university hospital in  
46 Germany. The primary outcome is the change in the autonomous functioning six months after surgery,  
47 measured via the Instrumental Activities of Daily Living (IADL, Lawton and Brody, 1969). The  
48 corresponding primary hypothesis is that individualized care of the patient as part of the PeriAge  
49 intervention enhances postoperative autonomy in comparison to the control group. We expect a  
50 smaller reduction of the IADL score in the experimental condition after one and six months.  
51 Additionally, we will test the composite effect of the PeriAge intervention on POCs, cognitive  
52 performance, length of inpatient stay, and several patient-relevant outcomes elaborated below.  
53  
54  
55

56  
57 Objective (2) of our study is to investigate the feasibility<sup>43</sup> of the PeriAge intervention, specifically its  
58 implementation and realisation in ongoing hospital operations. We intend to show that it is possible  
59  
60

1  
2  
3 to implement a multidimensional intervention into routine care and identify main challenges of  
4 implementation. The feasibility of the implementation is categorised after the elements practicability,  
5 acceptance, adoption, and fidelity to protocol.  
6  
7

## 8 9 **METHODS AND ANALYSIS**

10 **Study design** The PeriAge intervention will be evaluated in a monocentric, non-randomized, controlled  
11 study. The study consists of three successive arms, each six months in lengths (see figure 2), while  
12 lengths of arms remain subject to extension as required. Patients will be allocated in a predefined  
13 order; the project starts with the usual routine healthcare as control, followed by the implementation  
14 phase and concluded by the intervention phase. Simultaneous to the control phase, the individual  
15 components of the PeriAge intervention will be elaborated, and their implementation prepared. The  
16 implementation phase is used to implement the PeriAge intervention into routine care gradually,  
17 leaving space for adoption, tailoring, and modifications as necessary. With the start of the intervention  
18 phase onwards, the final PeriAge intervention will be administered and information of its feasibility  
19 will be gathered. The 3-year mixed-method project comprises two simultaneous branches, evaluating  
20 the feasibility and effectiveness of the PeriAge intervention, respectively.  
21  
22  
23  
24  
25  
26  
27  
28  
29

30 **Study population** Participants are patients aged above 64 with impending elective surgery in a  
31 university hospital of a German metropolitan region. In order to test the PeriAge intervention with  
32 high external validity, patients receiving all types of surgeries except for neurocerebral- and  
33 ophthalmologic surgeries will be included. While cognitive performance and functional status cannot  
34 be independently attributable to the interventions after neurocerebral surgeries, ophthalmologic  
35 surgeries take place at an external site within the university medical centre and execution of  
36 intraoperative interventions cannot be guaranteed. Exclusion criteria are emergency surgery, surgery  
37 within five days of indication, and surgery with planned postoperative intensive care or planned  
38 postoperative hospitalisation for fewer than 24 hours. Further, patients will be excluded who are  
39 analphabetic, who do not have sufficient command of the German language and patients who suffer  
40 from psychosis, illicit drug use, chronic use of benzodiazepines, and patients who suffer from an  
41 incorrigible auditory or visual disability.  
42  
43  
44  
45  
46  
47  
48  
49  
50

## 51 **Effectiveness assessment of the PeriAge intervention and its influences**

### 52 *Procedures and instruments*

53  
54 Within each arm, the study follows a pre-post design. Patient assessments take place once before  
55 intervention initiation and at three time points after intervention completion as shown in figure 2. All  
56 patients will undergo an extensive preanaesthetic evaluation (T0). In addition to the routine check-up,  
57 the assessment entails brief neuropsychological testing to evaluate the patient's cognitive state,  
58  
59  
60

1  
2  
3 strength and mobility testing and patient-reported outcome measures (PROMs) about somatic and  
4 mental health, current living situation and quality of life. Additionally, the responsible anaesthetist will  
5 record malnutrition (see table 1), demographics and the need for sensory aids. In the implementation  
6 and intervention group, the PeriAge intervention will be introduced.  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only



Table 1. Multidimensional perioperative assessment; instruments, type and time point of enquiry and direction of hypothesised effect.

Domain	Instrument	Operationalisation	Time point				exp. direction of effect**	
			T0	T1	T2	T3		
Social, physical and autonomous functioning	IADL*	functional status	x		x	x	↑	
	Social situation by Nikolaus <sup>44</sup>	social status	x				N/A	
	LUCAS-FI	frailty proxy	x		x	x	↓	
	MNA-SF	malnourishment	x				N/A	
	1 minute sit to stand test <sup>45,46</sup>	mobility	x		x	x	↑	
	Timed up & go test <sup>47</sup>	physical strength, stamina	x		x	x	↑	
orientation & cognition	vigrometer (hand force) <sup>48</sup>	physical strength	x	x	x	x	↑	
	CAM-ICU	delirium		x			↓	
	DemTect	cognitive functioning	x	x	x	x	↑	
	TAP alertness subtest		x	x	x	x	↑	
	TMT		x	x	x	x	↑	
quality of life & mental health	Subjective cognitive rating	sense of cognitive functioning	x	x	x	x	↑	
quality of life & mental health	SF-12 <sup>49</sup>	health-related quality of life	x		x	x	↑	
	GDS	depressive symptoms	x		x	x	↓	
	GAD-2	anxiety symptoms	x		x	x	↓	
somatic POCs	POSPOM	Postoperative mortality risk scoring	x				N/A	
	Patient blood management <sup>†</sup>	Deficiency states ( Hb, Transferritin, Ferritin)	x					
	EPR <sup>†</sup>	somatic complications (incl. mortality)			x	x	x	↓
	history assessment	length of hospitalisation			x			↓
	history assessment	polypharmacy	x				N/A	

**POC:** post-operative complications. **IADL:** Instrumental Activities of Daily Living. **LUCAS-I:** Longitudinal Urban Cohort Age Study - Instrument (Dapp, Anders, von Renteln-Kruse, et al., 2012). **MNA-SF:** Mini Nutritional Assessment - Short Form (©Nestlé Nutrition Institute, 1993). **CAM-ICU:** Confusion Assessment Method for Intensive Care Units (Ely, Margolin, Francis, et al., 2001). **DemTect:** Dementia Detection (Kalbe, Kessler, Calabrese, et al., 2004). **TAP:** Test battery for attentional performance (Zimmermann and Fimm, 1993). **TMT:** Trail Making Test (Reitan and Wolfson, 1992). **SF-12:** Short Form health survey (Bullinger and Kirchberger, 1998). **GDS:** Geriatric Depression Scale (Yesavage, Brink, Rose, et al., 1982). **GAD-2:** Generalized Anxiety Disorder 2 (Spitzer, Kroenke, Williams, et al., 2006). **POSPOM:** Preoperative Score to Predict Postoperative Mortality (Le Manach, Collins, Rodseth, et al., 2016). **EPR:** electronic patient record; \*primary effectiveness outcome, all instruments that are administered at T3 and the CAM-ICU will be interpreted as secondary outcomes; † does not fit the description of an instrument, but is listed here for completeness; \*\*the expected effect refers to the comparison between control and intervention group. An up-pointing arrow connotes a reduced respective decline in the intervention group, not more favourable outcomes postoperatively.

#### [FIGURE 2]

The first postoperative enquiry takes place (T1) within the first few days after surgery. At that point, delirium,<sup>52</sup> cognitive functioning,<sup>53-55</sup> physical strength,<sup>45,48</sup> and mobility<sup>46</sup> are assessed and information about somatic complications is extracted from the hospital's electronic patient record (EPR). POD is

1  
2  
3 screened for using the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) including  
4 modified Richmond Agitation and Sedation Scale (m-RASS) in the first five days following surgery  
5 according to guideline recommendations.<sup>60</sup> T2 and T3 take place one and six months after surgery  
6 respectively.  
7  
8  
9

10 Short-term outcomes are anaesthesia duration, duration of inpatient stay and the occurrence of  
11 somatic postoperative complications, including delirium and mortality. PROMs and a brief  
12 neurocognitive assessment, evaluating patient's postoperative cognitive abilities will be used as  
13 parameters to assessing long-term effects of the intervention, one and six months after surgery.  
14 PROMs are used to assess functional status, a proxy for frailty, health-related quality of life, and mental  
15 morbidity; the neurocognitive assessment focusses on alertness, cognitive flexibility, and working  
16 memory. See *table 1* for instruments, operationalisation, time point of assessment and expected  
17 direction of effects.  
18  
19  
20  
21  
22  
23

24 The proposed intervention components affect either the pre- or the intraoperative phase. While all  
25 intervention components shall counteract POC and decline of autonomy one and six months after  
26 surgery, the specific measures focus on different aspects of postoperative health. Special attention is  
27 given to everyday functioning; including nutritional and fitness status, orientation, and somatic  
28 complications (see figure 1). Malnourished patients will be provided with high-protein drinks for a  
29 maximum of 14 days up to the eve of their surgery day. Additionally, patients are offered a  
30 carbohydrate drink two hours prior to surgery to forestall potential glucose depletion,<sup>61</sup> but also to  
31 reduce preoperative anxiety and discomfort.<sup>62</sup> Patients with poor physical fitness are prompted to  
32 undergo preoperative progressive strength and fitness training, instructed via a short personal  
33 introduction and information brochures and logged by a self-report diary. All patients are suggested  
34 performing breathing exercises, taught by an information brochure.  
35  
36  
37  
38  
39  
40  
41  
42  
43

#### 44 *Interventions*

45 Intervention components to reduce mental overload and prevent disorientation comprise the  
46 inclusion of relatives, extensive information giving about planned procedures, and the preservation of  
47 sensory orientation. The systematic inclusion of relatives or significant others in all procedures from  
48 the beginning of the inpatient stay onwards shall counteract potential disorientation within the  
49 unfamiliar, and potentially highly stressful setting. A detailed and comprehensible pre-operation  
50 discussion including information about the inpatient stay and the scheduled POC prevention measures  
51 shall serve as an additional orientation aid. Patients will be encouraged to bring personal items at  
52 admission, such as pillows, photographs, and music. This shall support recognition and diminish the  
53 risk of suffering POD. Furthermore, patients with need for vision aids, acoustic instruments, and dental  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 prostheses are encouraged to retain these aids up to the anaesthetic induction to foster sensory  
4 orientation.  
5

6  
7 Measures to prevent somatic complications consist of screening and potential adjustment of  
8 potentially inadequate or multi-medication in accordance with national and international  
9 recommendations<sup>22,23</sup> and general refrainment from administering benzodiazepines. Patients with  
10 anaemia will be screened for iron deficiency. If an iron deficiency anaemia is diagnosed and the risk for  
11 intraoperative bleeding is estimated to be above 10%, patients will be supplemented with intravenous  
12 iron prior to surgery in accordance of the principles of Patient Blood Management.  
13  
14  
15  
16

17  
18 The proposed intraoperative measures shall prevent somatic complications and mental disorientation.  
19 The geriatric anaesthesia concept includes employing regional anaesthesia alone or in combination  
20 with general anaesthesia whenever possible to ensure an opioid-saving postoperative analgesia  
21 regime. When general anaesthesia is performed, BIS is used for neuromonitoring purposes. Further,  
22 certain medications will be avoided intraoperatively, in particular, benzodiazepines, atropine,  
23 anticholinergics, and central alpha-agonists. If muscle-relaxants are needed, short-acting substances  
24 are preferred as well as postoperative catheter-assisted analgesia. Thermal blankets from anaesthesia  
25 induction to post anaesthesia care will be given to the patient in order to avoid hypothermia. See figure  
26 1 for a comprehensive list of pre- and intraoperative risk-specific interventions.  
27  
28  
29  
30  
31  
32

33  
34 During the implementation and intervention phases, training events by study staff and external experts  
35 will be performed at every affected hospital ward and in anaesthesia meetings. These meetings inform  
36 about relevant topics of in-patient care such as the preoperative administration of carbohydrate  
37 drinks, measures of POD prevention, patient information and adequate postoperative analgesia in the  
38 elderly. Anaesthetists are instructed to follow the comprehensive administration of the BIS in surgery.  
39  
40  
41  
42

#### 43 *Recruitment/sample size*

44  
45 The required sample size is based on sufficient power for identifying rare foreseen and unforeseen  
46 incidents, as suggested for feasibility trials.<sup>63</sup> The emergence of POCs depends on underlying conditions  
47 and type of surgery conducted. In the elected cohort, the likelihood of an occurrence of POCs is  
48 considerably above 10%,<sup>64,65</sup> so is the risk of losing the level of preoperative functioning and autonomy.  
49 A sample size of 30 is minimally required for the identification of an event with an average occurrence  
50 of 10% with a confidence of 95%.<sup>63</sup> Because of an expected dropout greater than 30%, as is common  
51 in studies that are performed under routine conditions, together with the plan to analyse multiple  
52 outcomes, we aim to recruit 80 patients in each of the three study arms, resulting in approximately  
53 240 patients in total.  
54  
55  
56  
57  
58  
59  
60

### Data analysis

We plan to use the intention to treat (ITT) method to conduct the primary analyses. Missing values will be accounted for by using mixed modelling techniques. The data will be analysed using descriptive and inferential statistics. The effects of the intervention will be estimated by using segmented regressions.<sup>66-68</sup> For the effectiveness analyses, generalised two-level regression models (linear, logistic or Cox depending on the outcome) will be used. This enables a nuanced estimation of time- and intervention effects, taking into account time trends within- and between the groups. The first level connotes the progression of the individual patients and will be estimated in intercept and slope. The second level connotes the difference between persons, taking into account time and group-effects. Should the assumptions for segmented regressions be violated, the models will be adjusted accordingly. Propensity score methods will be used in case of strong violation.<sup>69</sup> Results with  $p < .05$  will be considered as statistically significant. As this study is of explorative nature, no adjustments will take place for multiple testing. However, the elevated risk of an occurrence of type-I errors will be regarded when interpreting the results.

### Feasibility assessment of the implementation

#### Procedures and instruments

A process evaluation is conducted to explore the feasibility of the PeriAge intervention. The critical elements for capturing the degree of feasibility in this study are acceptance of those affected, in particular patients and clinical staff, as well as the, practicability, realisation and adoption, accessibility of the intervention, and fidelity to protocol, chosen by means of the current standards of feasibility studies (see table 2).<sup>70-72</sup>

Table 2. Quantitative and qualitative feasibility assessment; type and description of analysis.

Domain	Operationalisation	Quantitative analysis	Qualitative analysis***	
		Brief description	Staff	Patient
Acceptance	Satisfaction with the intervention and its implementation	--	x	x
Practicability	Relevance of the intervention and compatibility with the specific setting	(Effectiveness outcomes, see above)	x	x
Realisation and adoption	Realisation: intend and action to employ the intervention Adoption: adjusted execution of the intervention to fit the setting and recording of these adjustments	- Data quality analysis on congruency, completeness, plausibility, and sources of potential errors. → reported and adapted if necessary - descriptive statistics of self-report diary and intervention checklist	x	

Accessibility	Penetration of intervention and access for all designated and eligible recipients	Evaluation of reasons for non-participation, recruitment progression and attrition rate Analysis of demographics and morbidity of dropouts	x
Fidelity to protocol	Quality and of intervention delivery and adherence to implementation protocol	Evaluation of implementation processes and interim adaptations by intervention checklist records	x

\*\*\*Thematic analysis evaluation of semi-structured interviews

Using a mixed method approach, the feasibility evaluation is segmented into a quantitative and a qualitative analysis. The quantitative analysis consists of continuous documentation of the realisation of the intervention from the implementation phase onwards (see figure 3).

[FIGURE 3]

An intervention checklist is filled in for every patient. This checklist is tailored on risk factors and interventions of the study and enquires about the proper execution of individual interventions e.g. the reduction of inappropriate polypharmacy, the retainment of orientation aids and the usage of the BIS during surgery. With this collection of process data deviations from the protocol can be prevented, or alternatively, detected. Additional plausibility analyses of the outcome data are performed.

For the qualitative feasibility analyses, information on the experience of the clinical and study staff and patients regarding the individual intervention components are collected and evaluated. Firstly, meeting logs of the project will be described. Secondly, semi-structured interviews will be conducted examining experience and opinion of the interviewee about adequacy and purpose of the intervention, as well as impediments and facilitators of the implementation process. The interviews will contain mainly open-ended questions. Interviewing patients and professionals of different contexts shall capture different perspectives on the implementation and increase the validity of the results. While the patient interviews will be held within the intervention phase after completing the T3 enquiry, the staff interviews will be conducted twice; once during the implementation phase and once after the termination of the intervention phase. The first staff interview serves not only as an inspection of feasibility, but also allows that necessary adjustments might be exposed and realised. The second interview repeats and finalises the inspection of feasibility.

#### *Recruitment/sample size*

Additional to the recruitment of 240 patients for the effectiveness analysis, it is planned to interview 5 to 10 study staff members medical assistants and clinicians, who are affected by the implementation. Additionally, seven randomly chosen patients of the intervention phase will be interviewed. These interviews take place after T3. The chosen sample size is based on experience and literature on saturation of information gain.<sup>73</sup>

### *Data analysis*

To perform the process evaluation, two structured analyses of the process- and outcome data will be performed on congruency and completeness in order to detect potential discrepancies between conception and realisations. The first analysis is conducted before initiation of the implementation phase and the second is conducted after the data collection is completed. The results of the evaluations as well as the results of the intervention checklist (see above), will be examined via descriptive statistics. The interviews will be recorded, transcribed and analysed by using a realist thematic analysis approach,<sup>74</sup> specifically a framework content analysis.<sup>75</sup> The thematic analysis approach is a method by which qualitative data is coded into themes (see figure 4). We will use a mainly deductive approach, as our feasibility outcomes are already pre-defined (see table 2). Coding schemes are developed beforehand and discussed regularly. Nevertheless, we are open to the possibility of inductive theme generation, if data suggests. The results will be reported using consolidated criteria for reporting qualitative research (COREQ).<sup>76</sup>

[FIGURE 4]

**Patient and public involvement** Patients and public were and will not be directly involved in the research study design. However, within the qualitative analysis, we will assess the patient's opinion of the PeriAge intervention, and about burden and time required to take part in this study. One research question is dedicated to obtain and integrate the patient's opinion into the results and eventually into the decision whether to continue and incorporate the programme in routine care. It is not planned to involve patients in the dissemination of the results. If the intervention shows to be feasible and brings added value into the healthcare of geriatric patients, it will be maintained and expanded to all wards and all surgical geriatric patients in the university medical centre Hamburg-Eppendorf.

**Software** Microsoft Access will be used for data collection, storage, and preparation. For most quantitative data analyses, it is anticipated to use the software R<sup>77</sup> and IBM SPSS Statistics<sup>78</sup>. Lastly, the software MAXQDA<sup>79</sup> will be used for qualitative data analyses.

### **ETHICS AND DISSEMINATION**

**Ethical and safety considerations** The study will be carried out according to the Helsinki Declaration of the World Medical Association. The principles of good scientific practice will be followed. Study participation is voluntary and may be withdrawn at any moment. Written informed consent will be obtained prior to participation. Patients will be fully educated about the aims and procedure of the study, data collection and the use of collected data. The rejection of participation has no negative consequences for patients and their care. No foreseeable risk at any moment results from the participation in this study. No compassionate use will be carried out. All intervention components are

1  
2  
3 non-invasive expect for the preoperative iron infusion if required according to the Patient Blood  
4 Management protocol. However, this is no experimental therapy method but an established and  
5 evidence-based measure, which is executed according to existing guidelines and approved by the  
6 local ethical review committee. Preserving principles of data sensitivity, data protection, and  
7 confidentiality requirements will be met. Significant deviations from the protocol, concerning  
8 recruitment, inclusion criteria, intervention, or statistical data analysis will be justified and discussed.  
9  
10 Modifications and amendments will be listed in the appendices of the main publication. SPIRIT  
11 reporting guidelines have been used to write protocol.<sup>80</sup>  
12  
13  
14  
15  
16

17  
18 **Dissemination plan** The results of the project will be published in scientific journals. In order to  
19 assure high accessibility, we aim to publish our work in open access journals, conditions permitting.  
20 Furthermore, the results will be presented at relevant national and international conferences.  
21 Additionally, a data basis shall be created that will help to inform clinical practice guidelines that  
22 enable and improve perioperative care and surgical outcomes of geriatric patients, respectively.  
23  
24  
25  
26

27  
28 **Data deposition** The collected data will be deposited on a protected server of the University Medical  
29 Centre Hamburg-Eppendorf, with strongly regulated access even for study personnel. Due to  
30 substantial obstacles to de-identification (relatively small sample, routine care, a large amount of  
31 qualitative data, etc.), individual participant data will not be shared publicly. Researchers who submit  
32 a methodologically sound proposal to the principal investigator that is approved by the responsible  
33 review committee will be allowed to use data.  
34  
35  
36  
37

### 38 **AUTHORS CONTRIBUTORS**

39 CO, MH, RK, and LK conceptualised the study, wrote the grant proposal, and obtained funding. LL,  
40 CO, AM, and LK designed the details of the study, with substantial contributions from MH and RK. RK  
41 is the responsible primary investigator of the project. LL and CO prepared the first draft of the  
42 manuscript. LP substantially contributed to implementing the individual interventions and the  
43 recruitment of patients. AEG and CZ, heads of the UKE Anaesthesiology department, supported and  
44 enabled the realisation of the study with their overall supervision. All authors contributed to critically  
45 revising the manuscript for important intellectual content, gave final approval of the version to be  
46 published, and agree to be accountable for the work as guarantors. The corresponding author attests  
47 that all listed authors meet authorship criteria and that no others meeting the criteria have been  
48 omitted.  
49  
50  
51  
52  
53  
54  
55  
56

57  
58 **Funding** This work is funded by the Innovation Fund of the German Federal Joint Committee  
59 (Gemeinsamer Bundesausschuss), with the grant number 01VSF16057 (contact information: phone  
60 +49 30 27 58380, email: info@g-ba.de). The German Federal Joint Committee reviewed and

approved the study design during the grant application process. It had no role in the conduct of the study and the publication process.

**Competing interests** None declared.

**Patient consent** Not required.

**Ethics approval** Ethics Committee of the Medical Association Hamburg, Germany (study ID: PV5596).

**Acknowledgements** G. Ketels and M. Lemke, both from the Department of Physiotherapy, UKE for the development and supervision of the prehabilitation-training program. R. Schulz, J. Jannsen, and C. Raschke: for performing as models in the prehabilitation brochure. C. Langebrake from the UKE Pharmacy for the supervision of the PeriAge medication reconciliation. C. Bergelt and G. Ohm from the UKE Developing department, for their support in submitting the grant proposal.

## REFERENCES

1. Fallpauschalenbezogene Krankenhausstatistik (DRG-Statistik), Diagnosen und Prozeduren der vollstationären Patientinnen und Patienten in Krankenhäusern Wiesbaden: Statistisches Bundesamt (Destatis); 2017 [17.08.2018]. Fachserie 12. Reihe 6.4:[Available from: <https://www.destatis.de/DE/Publikationen/Thematisch/Gesundheit/Krankenhaeuser/FallpauschalenKrankenhaus.html>].
2. Olotu-Steffen C, Gurlit S, Kiefmann R. Präoperative Vorbereitung und Evaluation: der ältere Patient. *Anästhesiol Intensivmed Notfallmed Schmerzther*. 2017;52(05):342-55.
3. Baquero GA, Rich MW. Perioperative care in older adults. *J Geriatr Cardiol*. 2015;12(5):465-9.
4. Deiner S, Westlake B, Dutton RP. Patterns of surgical care and complications in elderly adults. *J Am Geriatr Soc*. 2014;62(5):829-35.
5. Lienhart A AY, Pequignot F Survey of anesthesia-related mortality in France. *Anesthesiology*. 2006;105:1087-97.
6. Sepehri A, Beggs T, Hassan A, et al. The impact of frailty on outcomes after cardiac surgery: a systematic review. *J Thorac Cardiovasc Surg*. 2014;148(6):3110-7.
7. Patel N, Minhas JS, Chung EM. Risk Factors Associated with Cognitive Decline after Cardiac Surgery: A Systematic Review. *Cardiovasc Psychiatry Neurol*. 2015;2015:370612.
8. Rundshagen I. Postoperative cognitive dysfunction. *Dtsch Arztebl Int*. 2014;111(8):119-25.
9. Kim S, Brooks AK, Groban L. Preoperative assessment of the older surgical patient: honing in on geriatric syndromes. *Clin Interv Aging*. 2015;10:13-27.
10. Carlisle JB. Pre-operative co-morbidity and postoperative survival in the elderly: beyond one lunar orbit. *Anaesthesia*. 2014;69 Suppl 1:17-25.
11. Newman MF, Kirchner JL, Phillips-Bute B, et al. Longitudinal assessment of neurocognitive function after coronary-artery bypass surgery. *N Engl J Med*. 2001;344(6):395-402.
12. Scandrett KG, Zuckerbraun BS, Peitzman AB. Operative risk stratification in the older adult. *Surg Clin North Am*. 2015;95(1):149-72.
13. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. *J Gerontol A Biol Sci Med Sci*. 2001;56(3):M146-56.
14. Beggs T, Sepehri A, Szwajcer A, et al. Frailty and perioperative outcomes: a narrative review. *Can J Anaesth*. 2015;62(2):143-57.
15. Aunan JR, Watson MM, Hagland HR, et al. Molecular and biological hallmarks of ageing. *Br J Surg*. 2016;103(2):e29-46.



16. DAS-Taskforce, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften. S3 Leitlinie Analgesie, Sedierung und Delirmanagement in der Intensivmedizin (DAS-Leitlinie 2015): GMS Ger Med Sci; 2015 [Available from: <https://www.egms.de/static/de/journals/gms/2015-13/000223.shtml>].
17. Bauer JM, Volkert D, Wirth R, et al. Diagnostik der Mangelernährung des älteren Menschen. *Dtsch Med Wochenschr.* 2006;131(5):223-7.
18. Weimann A, Braga M, Harsanyi L, et al. ESPEN Guidelines on Enteral Nutrition: Surgery including organ transplantation. *Clin Nutr.* 2006;25(2):224-44.
19. Jack S, West M, Grocott MP. Perioperative exercise training in elderly subjects. *Best Pract Res Clin Anaesthesiol.* 2011;25(3):461-72.
20. Deutz NE, Bauer JM, Barazzoni R, et al. Protein intake and exercise for optimal muscle function with aging: recommendations from the ESPEN Expert Group. *Clin Nutr.* 2014;33(6):929-36.
21. Mohanty S, Rosenthal RA, Russell MM, et al. Optimal Perioperative Management of the Geriatric Patient: A Best Practices Guideline from the American College of Surgeons NSQIP and the American Geriatrics Society. *J Am Coll Surg.* 2016;222(5):930-47.
22. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. *J Am Geriatr Soc.* 2015;63(11):2227-46.
23. Holt S, Schmiedl S, Thurmann PA. Potentially inappropriate medications in the elderly: the PRISCUS list. *Dtsch Arztebl Int.* 2010;107(31-32):543-51.
24. Smith I, Kranke P, Murat I, et al. Perioperative fasting in adults and children: guidelines from the European Society of Anaesthesiology. *Eur J Anaesthesiol.* 2011;28(8):556-69.
25. Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin e.V. and Berufsverband Deutscher Anästhesisten e.V. Entschliefungen, Empfehlungen, Vereinbarungen. Ebelsbach: Aktiv Druck & Verlag GmbH; 2011.
26. Ali Abdelhamid Y, Chapman MJ, Deane AM. Peri-operative nutrition. *Anaesthesia.* 2016;71 Suppl 1:9-18.
27. Broadbent E, Petrie JK, Alley GP, et al. Psychological Stress Impairs Early Wound Repair Following Surgery. *Psychosom Med.* 2003.;65(5):865-9.
28. Wozniak SE, Coleman J, Katlic MR. Optimal Preoperative Evaluation and Perioperative Care of the Geriatric Patient: A Surgeon's Perspective. *Anesthesiol Clin.* 2015;33(3):481-9.
29. Inouye SK, Bogardus ST, Jr., Baker DI, et al. The Hospital Elder Life Program: a model of care to prevent cognitive and functional decline in older hospitalized patients. Hospital Elder Life Program. *J Am Geriatr Soc.* 2000;48(12):1697-706.
30. Munoz M, Acheson AG, Auerbach M, et al. International consensus statement on the peri-operative management of anaemia and iron deficiency. *Anaesthesia.* 2017;72(2):233-47.
31. Mehra T, Seifert B, Bravo-Reiter S, et al. Implementation of a patient blood management monitoring and feedback program significantly reduces transfusions and costs. *Transfusion.* 2015;55(12):2807-15.
32. Association of Anaesthetists of Great Britain and Ireland. Peri-operative care of the elderly 2014. *Anaesthesia.* 2014;69:81-98.
33. Gombotz H, Zacharowski K, Spahn DR, et al. Patient Blood Management. Stuttgart, New York: Georg Thieme Verlag; 2013. Available from: <https://www.thieme-connect.de/products/ebooks/book/10.1055/b-002-59191>.
34. Radtke FM, Franck M, Lendner J, et al. Monitoring depth of anaesthesia in a randomized trial decreases the rate of postoperative delirium but not postoperative cognitive dysfunction. *Br J Anaesth.* 2013;110 Suppl 1:i98-105.
35. Vaurio LE, Sands LP, Wang Y, et al. Postoperative delirium: the importance of pain and pain management. *Anesth Analg.* 2006;102(4):1267-73.
36. Rundshagen I. Anästhesiologische Strategien bei Hochbetagten. *Anästhesie und Intensivmedizin.* 2015;56:534-45.

- 1
- 2
- 3 37. Varadhan KK, Neal KR, Dejong CH, et al. The enhanced recovery after surgery (ERAS) pathway
- 4 for patients undergoing major elective open colorectal surgery: a meta-analysis of
- 5 randomized controlled trials. *Clin Nutr*. 2010;29(4):434-40.
- 6
- 7 38. Santa Mina D, Clarke H, Ritvo P, et al. Effect of total-body prehabilitation on postoperative
- 8 outcomes: a systematic review and meta-analysis. *Physiotherapy*. 2014;100(3):196-207.
- 9
- 10 39. Rubin FH, Williams JT, Lescisin DA, et al. Replicating the Hospital Elder Life Program in a
- 11 community hospital and demonstrating effectiveness using quality improvement
- 12 methodology. *J Am Geriatr Soc*. 2006;54(6):969-74.
- 13
- 14 40. Damschroder LJ, Aron DC, Keith RE, et al. Fostering implementation of health services
- 15 research findings into practice: a consolidated framework for advancing implementation
- 16 science. *Implement Sci*. 2009;4:50.
- 17
- 18 41. Partridge JS, Harari D, Martin FC, et al. The impact of pre-operative comprehensive geriatric
- 19 assessment on postoperative outcomes in older patients undergoing scheduled surgery: a
- 20 systematic review. *Anaesthesia*. 2014;69 Suppl 1:8-16.
- 21
- 22 42. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental
- 23 activities of daily living. *Gerontologist*. 1969;9(3):179-86.
- 24
- 25 43. Moore GF, Audrey S, Barker M, et al. Process evaluation of complex interventions: Medical
- 26 Research Council guidance. *Bmj*. 2015;350:h1258.
- 27
- 28 44. Zemke J. Erfassung der Sozialen Situation (SoS) nach Nikolaus. *GGP - Geriatrische und*
- 29 *Gerontologische Pflege*. 2018;02(06):260-2.
- 30
- 31 45. Millor N, Lecumberri P, Gomez M, et al. Gait Velocity and Chair Sit-Stand-Sit Performance
- 32 Improves Current Frailty-Status Identification. *IEEE Trans Neural Syst Rehabil Eng*. 2017.
- 33
- 34 46. Bohannon RW. Sit-to-stand test for measuring performance of lower extremity muscles.
- 35 *Percept Mot Skills*. 1995;80(1):163-6.
- 36
- 37 47. Podsiadlo D, Richardson S. The timed "Up & Go": a test of basic functional mobility for frail
- 38 elderly persons. *J Am Geriatr Soc*. 1991;39(2):142-8.
- 39
- 40 48. Phillips P. Grip strength, mental performance and nutritional status as indicators of mortality
- 41 risk among female geriatric patients. *Age Ageing*. 1986;15(1):53-6.
- 42
- 43 49. Ware JE, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: Construction of Scales
- 44 and Preliminary Tests of Reliability and Validity. *Med Care*. 1996;34(3):220-33.
- 45
- 46 50. Dapp U, Anders J, von Renteln-Kruse W, et al. The longitudinal urban cohort ageing study
- 47 (LUCAS): study protocol and participation in the first decade. *BMC Geriatr*. 2012;12(1):35.
- 48
- 49 51. Skates J, Anthony P. Identifying Geriatric Malnutrition in Nursing Practice: The Mini
- 50 Nutritional Assessment (MNA<sup>®</sup>)—An Evidence-Based Screening Tool. *J Gerontol Nurs*.
- 51 2012;38(3):18-27.
- 52
- 53 52. Ely EW, Margolin R, Francis J, et al. Evaluation of delirium in critically ill patients: validation of
- 54 the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU). *Crit Care Med*.
- 55 2001;29(7):1370-9.
- 56
- 57 53. Kalbe E, Kessler J, Calabrese P, et al. DemTect: a new, sensitive cognitive screening test to
- 58 support the diagnosis of mild cognitive impairment and early dementia. *Int J Geriatr*
- 59 *Psychiatry*. 2004;19(2):136-43.
- 60
54. Zimmermann P, Fimm B. A test battery for attentional performance. *Applied*
- neuropsychology of attention*: Psychology Press; 2004. p. 124-65.
55. Reitan RM, Wolfson D. Conventional intelligence measurements and neuropsychological
- concepts of adaptive abilities. *J Clin Psychol*. 1992;48(4):521-9.
56. Bullinger M, Kirchberger J. Der SF-36-Fragebogen zum Gesundheitszustand. *Hogrefe Verlag,*
- Göttingen*. 1998:65–72.
57. Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression
- screening scale: a preliminary report. *J Psychiatr Res*. 1982;17(1):37-49.
58. Spitzer RL, Kroenke K, Williams JB, et al. A brief measure for assessing generalized anxiety
- disorder: the GAD-7. *Arch Intern Med*. 2006;166(10):1092-7.

- 1
- 2
- 3 59. Le Manach Y, Collins G, Rodseth R, et al. Preoperative Score to Predict Postoperative Mortality (POSPOM) Derivation and Validation. *Anesthesiology*. 2016;124(3):570-9.
- 4
- 5 60. Aldecoa C, Bettelli G, Bilotta F, et al. European Society of Anaesthesiology evidence-based and consensus-based guideline on postoperative delirium. *Eur J Anaesthesiol*. 2017;34(4):192-214.
- 6
- 7
- 8 61. Smith MD, McCall J, Plank L, et al. Preoperative carbohydrate treatment for enhancing recovery after elective surgery. *Cochrane Database Syst Rev*. 2014(8):CD009161.
- 9
- 10 62. Kaška M, Grosmanová Tá, Havel E, et al. The impact and safety of preoperative oral or intravenous carbohydrate administration versus fasting in colorectal surgery – a randomized controlled trial. *Wien Klin Wochenschr*. 2010;122(1):23-30.
- 11
- 12 63. Viechtbauer W, Smits L, Kotz D, et al. A simple formula for the calculation of sample size in pilot studies. *J Clin Epidemiol*. 2015;68(11):1375-9.
- 13
- 14 64. Story DA. Postoperative complications in elderly patients and their significance for long-term prognosis. *Curr Opin Anaesthesiol*. 2008;21(3):375-9.
- 15
- 16 65. McNicol L, Story DA, Leslie K, et al. Postoperative complications and mortality in older patients having non-cardiac surgery at three Melbourne teaching hospitals. *Med J Aust*. 2007;186(9):447-52.
- 17
- 18 66. Wagner AK, Soumerai SB, Zhang F, et al. Segmented regression analysis of interrupted time series studies in medication use research. *J Clin Pharm Ther*. 2002;27(4):299-309.
- 19
- 20 67. Gebski V, Ellingson K, Edwards J, et al. Modelling interrupted time series to evaluate prevention and control of infection in healthcare. *Epidemiol Infect*. 2012;140(12):2131-41.
- 21
- 22 68. Kontopantelis E, Doran T, Springate DA, et al. Regression based quasi-experimental approach when randomisation is not an option: interrupted time series analysis. *Bmj*. 2015;350:h2750.
- 23
- 24 69. Rosenbaum PR, RD. The central role of the propensity score in observational studies for causal effects. *Biometrika*. 1983;70:41-55.
- 25
- 26 70. Craig P, Dieppe P, Macintyre S, et al. Developing and evaluating complex interventions: the new Medical Research Council guidance. *Bmj*. 2008;337:a1655.
- 27
- 28 71. Glasgow RE, McKay HG, Piette JD, et al. The RE-AIM framework for evaluating interventions: what can it tell us about approaches to chronic illness management? *Patient Educ Couns*. 2001;44(2):119-27.
- 29
- 30 72. Proctor E, Silmere H, Raghavan R, et al. Outcomes for implementation research: conceptual distinctions, measurement challenges, and research agenda. *Adm Policy Ment Health*. 2011;38.
- 31
- 32 73. Marshall MN. Sampling for qualitative research. *Fam Pract*. 1996;13(6):522-5.
- 33
- 34 74. Braun V, Clarke V. Using thematic analysis in psychology. *Qual Res Psychol*. 2006;3(2):77-101.
- 35
- 36 75. Gale NK, Heath G, Cameron E, et al. Using the framework method for the analysis of qualitative data in multi-disciplinary health research. *BMC Med Res Methodol*. 2013;13(1):117.
- 37
- 38 76. Tong A, Craig J, Sainsbury P. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. *Int J Qual Health Care*. 2007;19(6):349-57.
- 39
- 40 77. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing. Vienna, Austria. URL <http://www.R-project.org/>. 2013.
- 41
- 42 78. IBM Corp. Released 2017. IBM SPSS Statistics for Windows VA, NY: IBM Corp.
- 43
- 44 79. VERBI S. MAXQDA 2018 [computer software]. Berlin, Germany: VERBI Software. Available from <https://www.maxqda.com2017>.
- 45
- 46 80. Chan A-W, Tetzlaff JM, Gøtzsche PC, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. *Bmj*. 2013;346:e7586.
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60





Figure 1. Age- and treatment related risk factors for developing POCs after surgery. In this study, these factors will be screened for in the preanaesthetic evaluation and corresponding preventive interventions will take place perioperatively if required and possible. Icons are used with permission from ©2018 Icons8 LLC, <https://icons8.com/>).

270x263mm (150 x 150 DPI)



32  
33  
34  
35  
36

Figure 2. Sequential study design. Allocation randomisation is not feasible, due to the risk of contamination or cross over between groups. During the control and implementation phase, the intervention components will be developed, the implementation planned and gradually introduced. In the intervention phase, the exhaustive intervention will be applied. The enquiry period, entailing recruitment and follow up of all phases, will be realised within 18 months.

37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

402x311mm (150 x 150 DPI)




Figure 3. Incorporation of the implementation and feasibility assessment within the study outline. From the implementation phase onwards up to the completion of the intervention phase, the quantitative and qualitative feasibility analyses will be performed.

489x277mm (150 x 150 DPI)




Figure 4. Scheme of theme coding of qualitative feasibility interviews. Potential statements of patients and staff are coded into the different organising aspects of the global feasibility theme.

435x300mm (150 x 150 DPI)

# Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

## Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin J, Doré C, Parulekar W, Summerskill W, Groves T, Schulz K, Sox H, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. *Ann Intern Med.* 2013;158(3):200-207

		Reporting Item	Page Number
<b>Administrative information</b>			
Title	<a href="#">#1</a>	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	<a href="#">#2a</a>	Trial identifier and registry name. If not yet registered, name of intended registry	2
Trial registration: data set	<a href="#">#2b</a>	All items from the World Health Organization Trial Registration Data Set	2
Protocol version	<a href="#">#3</a>	Date and version identifier	1
Funding	<a href="#">#4</a>	Sources and types of financial, material, and other support	13



1	Roles and	<a href="#">#5a</a>	Names, affiliations, and roles of protocol contributors	1, 12
2	responsibilities:			
3	contributorship			
4				
5				
6	Roles and	<a href="#">#5b</a>	Name and contact information for the trial sponsor	13
7	responsibilities:			
8	sponsor contact			
9	information			
10				
11				
12				
13	Roles and	<a href="#">#5c</a>	Role of study sponsor and funders, if any, in study	13
14	responsibilities:		design; collection, management, analysis, and	
15	sponsor and funder		interpretation of data; writing of the report; and the	
16			decision to submit the report for publication, including	
17			whether they will have ultimate authority over any of	
18			these activities	
19				
20				
21				
22				
23	Roles and	<a href="#">#5d</a>	Composition, roles, and responsibilities of the	13
24	responsibilities:		coordinating centre, steering committee, endpoint	
25	committees		adjudication committee, data management team, and	
26			other individuals or groups overseeing the trial, if	
27			applicable (see Item 21a for data monitoring committee)	
28				
29				
30				
31	<b>Introduction</b>			
32				
33	Background and	<a href="#">#6a</a>	Description of research question and justification for	3
34	rationale		undertaking the trial, including summary of relevant	
35			studies (published and unpublished) examining benefits	
36			and harms for each intervention	
37				
38				
39				
40	Background and	<a href="#">#6b</a>	Explanation for choice of comparators	4
41	rationale: choice of			
42	comparators			
43				
44				
45	Objectives	<a href="#">#7</a>	Specific objectives or hypotheses	4
46				
47				
48	Trial design	<a href="#">#8</a>	Description of trial design including type of trial (eg,	5
49			parallel group, crossover, factorial, single group),	
50			allocation ratio, and framework (eg, superiority,	
51			equivalence, non-inferiority, exploratory)	
52				
53				

54  
55 **Methods:**  
56 **Participants,**  
57

## interventions, and outcomes

Study setting	<a href="#">#9</a>	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	5
Eligibility criteria	<a href="#">#10</a>	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	5
Interventions: description	<a href="#">#11a</a>	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	8
Interventions: modifications	<a href="#">#11b</a>	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving / worsening disease)	9
Interventions: adherence	<a href="#">#11c</a>	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return; laboratory tests)	9
Interventions: concomitant care	<a href="#">#11d</a>	Relevant concomitant care and interventions that are permitted or prohibited during the trial	n/a
Outcomes	<a href="#">#12</a>	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	6,7,10
Participant timeline	<a href="#">#13</a>	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	6
Sample size	<a href="#">#14</a>	Estimated number of participants needed to achieve study objectives and how it was determined, including	6

clinical and statistical assumptions supporting any sample size calculations

Recruitment [#15](#) Strategies for achieving adequate participant enrolment to reach target sample size 8,11

## Methods:

### Assignment of interventions (for controlled trials)

Allocation: sequence generation [#16a](#) Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions 5

Allocation concealment mechanism [#16b](#) Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned 5

Allocation: implementation [#16c](#) Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions 5

Blinding (masking) [#17a](#) Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how n/a

Blinding (masking): emergency unblinding [#17b](#) If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial n/a

### Methods: Data collection, management, and analysis

Data collection plan [#18a](#) Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate 6,8

measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	<p>Data collection plan: retention</p> <p>Data management</p> <p>Statistics: outcomes</p> <p>Statistics: additional analyses</p> <p>Statistics: analysis population and missing data</p> <p><b>Methods: Monitoring</b></p> <p>Data monitoring: formal committee</p> <p>Data monitoring: interim analysis</p>	<p><a href="#">#18b</a> Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols</p> <p><a href="#">#19</a> Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol</p> <p><a href="#">#20a</a> Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol</p> <p><a href="#">#20b</a> Methods for any additional analyses (eg, subgroup and adjusted analyses)</p> <p><a href="#">#20c</a> Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)</p> <p><b>#21a</b> Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed</p> <p><b>#21b</b> Description of any interim analyses and stopping guidelines, including who will have access to these</p>	<p>9,11</p> <p>9.11</p> <p>9,11</p> <p>9,11</p> <p>9,11</p> <p>n/a</p> <p>n/a</p>
---	--	---	---

1			interim results and make the final decision to terminate	
2			the trial	
3				
4	Harms	<a href="#">#22</a>	Plans for collecting, assessing, reporting, and managing	12
5			solicited and spontaneously reported adverse events	
6			and other unintended effects of trial interventions or trial	
7			conduct	
8				
9				
10				
11	Auditing	<a href="#">#23</a>	Frequency and procedures for auditing trial conduct, if	n/a
12			any, and whether the process will be independent from	
13			investigators and the sponsor	
14				
15				
16	<b>Ethics and</b>			
17	<b>dissemination</b>			
18				
19				
20	Research ethics	<a href="#">#24</a>	Plans for seeking research ethics committee /	12
21	approval		institutional review board (REC / IRB) approval	
22				
23				
24	Protocol amendments	<a href="#">#25</a>	Plans for communicating important protocol	12
25			modifications (eg, changes to eligibility criteria,	
26			outcomes, analyses) to relevant parties (eg,	
27			investigators, REC / IRBs, trial participants, trial	
28			registries, journals, regulators)	
29				
30				
31				
32	Consent or assent	<a href="#">#26a</a>	Who will obtain informed consent or assent from	12
33			potential trial participants or authorised surrogates, and	
34			how (see Item 32)	
35				
36				
37	Consent or assent:	<a href="#">#26b</a>	Additional consent provisions for collection and use of	n/a
38	ancillary studies		participant data and biological specimens in ancillary	
39			studies, if applicable	
40				
41				
42				
43	Confidentiality	<a href="#">#27</a>	How personal information about potential and enrolled	12
44			participants will be collected, shared, and maintained in	
45			order to protect confidentiality before, during, and after	
46			the trial	
47				
48				
49	Declaration of	<a href="#">#28</a>	Financial and other competing interests for principal	13
50	interests		investigators for the overall trial and each study site	
51				
52				
53	Data access	<a href="#">#29</a>	Statement of who will have access to the final trial	12
54			dataset, and disclosure of contractual agreements that	
55			limit such access for investigators	
56				
57				
58				
59				
60				

1	Ancillary and post trial	<a href="#">#30</a>	Provisions, if any, for ancillary and post-trial care, and for	n/a
2	care		compensation to those who suffer harm from trial	
3			participation	
4				
5				
6	Dissemination policy:	<a href="#">#31a</a>	Plans for investigators and sponsor to communicate trial	12
7	trial results		results to participants, healthcare professionals, the	
8			public, and other relevant groups (eg, via publication,	
9			reporting in results databases, or other data sharing	
10			arrangements), including any publication restrictions	
11				
12				
13				
14	Dissemination policy:	<a href="#">#31b</a>	Authorship eligibility guidelines and any intended use of	12
15	authorship		professional writers	
16				
17				
18	Dissemination policy:	<a href="#">#31c</a>	Plans, if any, for granting public access to the full	12
19	reproducible research		protocol, participant-level dataset, and statistical code	
20				
21				
22	<b>Appendices</b>			
23				
24	Informed consent	<a href="#">#32</a>	Model consent form and other related documentation	19
25	materials		given to participants and authorised surrogates	
26				
27				
28	Biological specimens	<a href="#">#33</a>	Plans for collection, laboratory evaluation, and storage of	n/a
29			biological specimens for genetic or molecular analysis in	
30			the current trial and for future use in ancillary studies, if	
31			applicable	
32				
33				
34				

35 The SPIRIT checklist is distributed under the terms of the Creative Commons Attribution License CC-  
 36 BY-ND 3.0. This checklist was completed on 15. May 2019 using <https://www.goodreports.org/>, a tool  
 37 made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)  
 38  
 39  
 40  
 41  
 42

#### 43 **Reasons for n/a:**

#### 46 **Interventions: concomitant care:**

47 as this study is conducted under routine care conditions, all concomitant care is permitted for all  
 48 patients at all times.  
 49

#### 51 **Data monitoring: formal committee:**

52 This is a pilot study, including a process evaluation in which data is monitored as part of the outcome.  
 53  
 54

#### 55 **Data monitoring: interim analysis:**

56 No interim analysis of the effectiveness subsection of the study is done. Data quality (consistence  
 57 and completeness) is checked for 6 months into recruitment as part of the process evaluation.  
 58  
 59

**Auditing:**

In this pilot study no auditing planned. However in the course of the process evaluation, internal auditing is planned to reveal flaws and deficiencies.

**Consent or assent: ancillary studies:**

No ancillary studies planned, no biological specimens used.

**Ancillary and post trial care:**

No ancillary studies planned, no post-trial care and no harm in this study.

**Biological specimens:**

None used

For peer review only

# BMJ Open

## Improvement of perioperative care of the elderly patient (PeriAge): protocol of a controlled interventional feasibility study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-031837.R1
Article Type:	Protocol
Date Submitted by the Author:	30-Aug-2019
Complete List of Authors:	Olotu, Cynthia; University Medical Center Hamburg-Eppendorf, Department of Anaesthesiology Lebherz, Lisa; University Medical Center Hamburg-Eppendorf, Department of Medical Psychology Härter, Martin; University Medical Center Hamburg-Eppendorf, Department of Medical Psychology Mende, Anna; University Medical Center Hamburg-Eppendorf, Department of Anaesthesiology Plümer, Lili; University Medical Center Hamburg-Eppendorf, Department of Anaesthesiology Goetz, Alwin E; University Medical Center Hamburg-Eppendorf, Department of Anaesthesiology Zöllner, Christian; University Medical Center Hamburg-Eppendorf, Department of Anaesthesiology Kriston, Levente ; University Medical Center Hamburg-Eppendorf, Germany, Medical Psychology Kiefmann, Rainer; University Medical Center Hamburg-Eppendorf, Department of Anaesthesiology
<b>Primary Subject Heading</b>:	Anaesthesia
Secondary Subject Heading:	Geriatric medicine, Patient-centred medicine, Qualitative research, Surgery, Evidence based practice
Keywords:	feasibility, perioperative care, geriatric anaesthesia, anaesthesiology, post-operative complications, patient-reported outcomes

SCHOLARONE™  
Manuscripts



## Improvement of perioperative care of the elderly patient (PeriAge): protocol of a controlled interventional feasibility study

Cynthia Olotu<sup>\*1</sup>, Lisa Lebherz<sup>\*2</sup>, Martin Härter<sup>2</sup>, Anna Mende<sup>1</sup>, Lili Plümer<sup>1</sup>, Alwin E Goetz<sup>1</sup>, Christian Zöllner<sup>1</sup>, Levente Kriston<sup>†2</sup>, Rainer Kiefmann<sup>†1</sup>

<sup>1</sup>Department of Anaesthesiology, University Medical Centre Hamburg-Eppendorf (UKE), Martinistraße 52, 20246 Hamburg, Germany.

<sup>2</sup>Department of Medical Psychology, University Medical Centre Hamburg-Eppendorf (UKE), Martinistraße 52, 20246 Hamburg, Germany.

\* CO and LL contributed equally to this paper

† LK and RK contributed equally to this paper

Email addresses:	Cynthia Olotu (CO)	c.olotu@uke.de
	Lisa Lebherz (LL)	l.lebherz@uke.de
	Martin Härter (MH)	m.haerter@uke.de
	Anna Mende (AM)	a.bader@uke.de
	Lili Plümer (LP)	l.pluemer@uke.de
	Alwin E. Goetz (AEG)	agoetz@uke.de
	Christian Zöllner (CZ)	c.zoellner@uke.de
	Levente Kriston (LK)	l.kriston@uke.de
	Rainer Kiefmann (RK)	r.kiefmann@uke.de

Corresponding author:

Lisa Lebherz, MSc.  
Department of Medical Psychology  
University Medical Centre Hamburg-Eppendorf (UKE)  
Martinistraße 52  
20246 Hamburg, Germany  
Email: l.lebherz@uke.de  
Phone: +49 (0)40 7410 57313

Date: 21.05.2019

Study start: 01.11.2017 (after study registration; start of the intervention phase, thus the “experimental condition” was 01.03.2019)

Protocol Version: 2

Word Count: 3616 words (excluding title page, abstract, tables, figures, author’s contributions, and references)

## ABSTRACT

**Introduction** Geriatric patients have a pronounced risk to suffer from postoperative complications. While effective risk-specific perioperative measures have been studied in controlled experimental settings, they are rarely found in routine healthcare. This study aims (1) to implement a multicomponent pre- and intraoperative intervention, and investigate its feasibility, and (2) exploratorily assess the effectiveness of the intervention in routine healthcare.

**Methods and analysis** Feasibility and exploratory effectiveness of the intervention will be investigated in a monocentric, prospective, non-randomised, controlled trial. The intervention includes systematic information for patients and family about measures to prevent postoperative complications; preoperative screening for frailty, malnutrition, strength and mobility with nutrient supplementation, and physical exercise (prehabilitation) as needed. Further components focus on potentially inadequate medication, patient blood-management and carbohydrate loading prior to surgery, retainment of orientation aids in the operating room, and a geriatric anaesthesia concept. Data will successively be collected from control, implementation, and intervention groups. Patients aged 65+ with impending surgery will be included. A sample size of 240, n=80 per group, is planned. Assessments will take place at inclusion and 2, 30, and 180 days after surgery. Mixed-methods analyses will be performed. Exploratory effectiveness will be assessed using mixed segmented regressions. The primary endpoint is functional status. Secondary endpoints include cognitive performance, health-related quality of life, length of inpatient stay and occurrence of postoperative complications. Feasibility will be assessed through semi-structured interviews with staff and patients and quantitative analyses of the data quality, focussing on practicability, acceptance, adoption, and fidelity to protocol.

**Ethics and dissemination** The study will be carried out in accordance with the Helsinki Declaration and to principles of good scientific practice. The Ethics Committee of the Medical Association Hamburg, Germany approved the protocol (study ID: PV5596). Results will be disseminated in scientific journals and healthcare conferences.

**Trial registration** ClinicalTrials.gov Identifier: NCT03325413.

**Keywords** feasibility, perioperative care, elderly, geriatric anaesthesia, anaesthesiology, post-operative complications, complex interventions, instrumental activities of daily life, quality of life, patient-reported outcomes, process evaluation.

### Strengths and limitations of this study

- |   |   |
|---|---|
| + | Feasibility AND exploratory effectiveness evaluation of a multicomponent pre- and intraoperative intervention under real-life circumstances for a variety of surgeries and with few inclusion restrictions. |
| + | High patient relevance due to the use of a wide range of patient-reported outcome measures and long term follow-up  |
| - | Capturing multidisciplinary experience from anaesthetists, medical assistants, nurses, and patients.  |
| - | Difficulties to implement and control for all intervention components adequately due to real-life circumstances.  |
|   | Risk of selection and attrition bias due to the non-randomized design and selective dropout.  |

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## INTRODUCTION

In Germany, every second inpatient surgical procedure is performed on patients aged 65 years and above.<sup>1</sup> This cohort has an elevated risk to suffer from a range of postoperative complications (POCs).<sup>2-6</sup> These include postoperative delirium (POD), pulmonary infection, cardiovascular events and an overall higher rate of postoperative morbidity, consequentially extended hospitalisations, and mortality, but also long-term general decline of health, cognition, functional status, and quality of life after surgery.<sup>7-11</sup> Further, immediate POCs can result in and amplify long-term decline of health and long-term loss of functional independence and quality of life. The most common patient-related risk factors are a reduced functional status, (i.a. sensory and cognitive impairment, poor physical fitness and mobility, malnutrition, polypharmacy, and multi-morbidity).<sup>12-15</sup> Treatment-associated risk factors include excessive fasting prior to surgery, dehydration, disorientation, disturbed sleep-wake-cycle, potential-inadequate medication, anxiety, mental overload and -stress, pain, hypothermia, loss of sensory orientation during in-patient stay,<sup>16</sup> and high invasiveness of the anaesthetic procedures and surgery.

In order to reduce POCs and generally improve clinical outcomes in elderly patients, it is important to detect patient-related risk factors prior to surgery and implement appropriate prophylactic measures. Accordingly, risk-specific prehabilitative interventions need to find their way into routine healthcare<sup>12</sup>. Evidence is consistent that preoperative prehabilitative measures can reduce the postoperative risk suffering POCs for elderly patients and hence improve long-term functional status. Protective measures include countering malnutrition,<sup>17,18</sup> poor physical fitness,<sup>19,20</sup> and enhancing breathing exercise techniques,<sup>21</sup> as well as reducing potentially inappropriate or multi-medication.<sup>22,23</sup> Handling of preoperative fasting is another problematic aspect of perioperative care. While guidelines support that 6 hours of preoperative fasting are sufficient in most cases, this is hardly met in clinical practice.<sup>24,25</sup> Recent studies, however, point out the protective effect of preoperative carbohydrate intake on the postoperative outcome, especially in vulnerable patients.<sup>26</sup> Further risk factors for less favourable postoperative outcomes are anxiety and psychological and mental stress. While the necessity of an inpatient surgery alone provokes a stress reaction, so does the entire medical procedure, from preanaesthetic evaluation to inpatient discharge. Last, but not least caused by the unfamiliar environment and the uncertainty of the outcome. This holds particularly true for potentially vulnerable patient groups, as is the geriatric cohort. Stress is well established to negatively impact somatic and mental health outcomes.<sup>27</sup> However, loss of orientation and high levels of stress can be reduced by marginal changes in routine preoperative procedures. Patients can be re-oriented by retaining glasses and hearing aids up to the anaesthetic induction, and by reducing mental stress and overload. This can be done by ensuring that the patient understands the procedures for surgery and therapy and by encouraging the presence and involvement of relatives,<sup>28</sup> which in turn may lead to a higher preservation of preoperative self-reliance and health-related quality of life.<sup>29</sup>

1  
2  
3 Further, the risk of different intraoperative procedures should be taken into consideration. The risk of  
4 suffering POCs is increased in patients, who have blood deficiency states and undergo sanguineous  
5 surgery, this risk can be reduced by individualised iron substitution.<sup>30-33</sup> It is recommended to monitor  
6 the depth of anaesthesia using e.g. bispectral index (BIS) analysis, as deep anaesthesia is associated  
7 with a higher incidence of postoperative delirium.<sup>34</sup> Postoperative pain is a predisposing factor for  
8 POCs.<sup>35</sup> To enable sufficient postoperative, opioid-saving analgesia, the use of catheter-assisted  
9 regional anaesthesia is preferable for elderly patients.<sup>32,36</sup>

15 While these risk factors are well studied and several intervention components have been shown to  
16 reduce complication rates in controlled research settings,<sup>37-39</sup> many effective intervention components  
17 are not used in routine care,<sup>40,41</sup> as both an extensive preoperative risk assessment and the  
18 administration of pre- and intraoperative measures are time-consuming and costly.

23 To improve the geriatric patient's postoperative safety and health, the preanaesthetic evaluation  
24 needs to be updated to the current state of research of risk- and preventive factors. Feasibility and  
25 benefit of an extended preanaesthetic evaluation and the ensuing administration of corresponding  
26 prophylactic interventions need to be demonstrated, in that it is possible to improve the pre- and  
27 intraoperative care of geriatric patients with feasible effort, leading to an overall reduction in long-  
28 term physical and cognitive complications as well as a reduced hospitalisation period.

33 **Objectives** In this study, a demand- and risk-based intervention (PeriAge-intervention) is developed  
34 and implemented into routine healthcare.

37 Objective (1) is to assess and provide exploratory evidence of the effectiveness of the PeriAge-  
38 intervention, improving the postoperative outcome of a sample of elderly patients at a university  
39 hospital in Germany. The primary outcome is the change in the autonomous functioning after surgery,  
40 measured via the Instrumental Activities of Daily Living (IADL, Lawton and Brody, 1969).<sup>42</sup> The  
41 corresponding primary hypothesis is that individualized care of the patient as part of the PeriAge  
42 intervention enhances postoperative autonomy in comparison to the control group. We expect a  
43 smaller reduction of the IADL score in the experimental condition after one, and six months.  
44 Additionally, we will test the composite effect of the PeriAge intervention on POCs, cognitive  
45 performance, length of inpatient stay, and several patient-relevant outcomes elaborated below.

53 Objective (2) of our study is to investigate the feasibility<sup>43</sup> of the PeriAge intervention, specifically its  
54 implementation and realisation in ongoing hospital operations. We intend to show that it is possible  
55 to implement a multidimensional intervention into routine care and identify main challenges of  
56 implementation. The feasibility of the implementation is categorised after the elements practicability,  
57 acceptance, adoption, and fidelity to protocol.

## METHODS AND ANALYSIS

**Study design** The PeriAge intervention will be evaluated in a monocentric, non-randomized, controlled study. The study consists of three successive arms, each six months in lengths (see figure 1), while lengths of arms remain subject to extension as required. Patients will be allocated in a predefined order; the project starts with the usual routine healthcare as control, followed by the implementation phase and concluded by the intervention phase. Simultaneous to the control phase, the individual components of the PeriAge intervention will be elaborated, and their implementation prepared. The implementation phase is used to implement the PeriAge intervention into routine care gradually, leaving space for adoption, tailoring, and modifications as necessary. With the start of the intervention phase onwards, the final PeriAge intervention will be administered and information of its feasibility will be gathered. The 3-year mixed-method project comprises two simultaneous branches, evaluating the feasibility and effectiveness of the PeriAge intervention, respectively. For reasons of clarity and comprehensibility, the exploratory effectiveness evaluation will be discussed first.

[FIGURE 1]

**Study population** Participants are patients aged above 64 with impending elective surgery in a university hospital of a German metropolitan region. In order to test the PeriAge intervention with high external validity, patients receiving all types of surgeries except for neurocerebral- and ophthalmologic surgeries will be included. While cognitive performance and functional status cannot be independently attributable to the interventions after neurocerebral surgeries, ophthalmologic surgeries take place at an external site within the university medical centre and execution of intraoperative interventions cannot be guaranteed. Exclusion criteria are emergency surgery, surgery within five days of study inclusion (premedication visit), and surgery with planned postoperative intensive care unit admission or planned postoperative hospitalisation for fewer than 24 hours. Patients that undergo the enhanced recovery after surgery ERAS® programme<sup>44</sup> are excluded. Further, patients will be excluded who are analphabetic, who do not have sufficient command of the German language and patients who suffer from psychosis, illicit drug use, chronic use of benzodiazepines, and patients who suffer from an incorrigible auditory or visual disability.

### Effectiveness assessment of the PeriAge intervention and its influences

#### *Procedures and instruments*

Within each arm, the study follows a pre-post design. Patient assessments take place once before intervention initiation and at three time points after intervention completion as shown in figure 1. All patients will undergo an extensive preanaesthetic evaluation (T0). In addition to the routine check-up, the assessment entails brief neuropsychological testing, to evaluate the patient's cognitive state,

1  
2  
3 strength and mobility testing and patient-reported outcome measures (PROMs) about somatic and  
4 mental health, current living situation, and quality of life (see table 1). Additionally, the responsible  
5 anaesthetist will record malnutrition, demographics, and the need for sensory aids. In the  
6 implementation and intervention group the PeriAge intervention will be introduced. However, the  
7 implementation group is merely recruited to gradually introduce and adjust the intervention if  
8 necessary, to guarantee a fully working and unbiased intervention during the assessment period of the  
9 intervention group.  
10  
11  
12  
13  
14

15 Table 1. Multidimensional perioperative assessment; instruments, type and time point of enquiry and  
16 direction of hypothesised effect.  
17

Domain	Instrument	Operationalisation	Time point				exp.
			T0	T1	T2	T3	direction of effect**
Social, physical and autonomou s functioning	IADL <sup>42*</sup>	functional status	x		x	x	↑
	Social situation by Nikolaus <sup>45</sup>	social status	x				N/A
	1 minute sit to stand test <sup>46,47</sup>	mobility	x		x	x	↑
	Timed up & go test <sup>48</sup>	physical strength, stamina	x		x	x	↑
	Vigrometer (hand force) <sup>49</sup>	physical strength	x	x	x	x	↑
	LUCAS-FI <sup>50</sup>	frailty proxy	x		x	x	↓
	MNA-SF <sup>51</sup>	malnourishment	x				N/A
orientation & cognition	CAM-ICU <sup>52</sup>	delirium		x			↓
	DemTect <sup>53</sup>	cognitive functioning	x	x	x	x	↑
	TAP alertness subtest <sup>54</sup>		x	x	x	x	↑
	TMT <sup>55</sup>		x	x	x	x	↑
	Subjective cognitive rating	sense of cognitive functioning	x	x	x	x	↑
quality of life & mental health	SF-12 <sup>56,57</sup>	health-related quality of life	x		x	x	↑
	GDS <sup>58</sup>	depressive symptoms	x		x	x	↓
	GAD-2 <sup>59</sup>	anxiety symptoms	x		x	x	↓
	POSPOM <sup>60</sup>	Postoperative mortality risk scoring	x				N/A

Patient blood management†	Deficiency states ( Hb, Transferritin, Ferritin)	x				N/A
EPR†	somatic complications (incl. mortality)	x	x	x		↓
EPR	length of hospitalisation	x				↓
history assessment	polypharmacy	x				N/A
IADL*	functional status	x	x	x		↑

**POC:** post-operative complications. **IADL:** Instrumental Activities of Daily Living. **LUCAS-I:** Longitudinal Urban Cohort Age Study - Instrument (Dapp, Anders, von Renteln-Kruse et al., 2012). **MNA-SF:** Mini Nutritional Assessment- Short Form (©Nestlé Nutrition Institute, 1993). **CAM-ICU:** Confusion Assessment Method for Intensive Care Units (Ely, Margolin, Francis et al., 2001). **DemTect:** Dementia Detection (Kalbe, Kessler, Calabrese et al., 2004). **TAP:** Test battery for attentional performance (Zimmermann and Fimm, 1993). **TMT:** Trail Making Test (Reitan and Wolfson, 1992). **SF-12:** Short Form (12) health survey (Bullinger and Kirchberger, 1998). **GDS:** Geriatric Depression Scale (Yesavage, Brink, Rose et al., 1982). **GAD-2:** Generalized Anxiety Disorder 2 (Spitzer, Kroenke, Williams et al., 2006). **POSPOM:** Preoperative Score to Predict Postoperative Mortality (Le Manach, Collins, Rodseth et al., 2016). **EPR:** electronic patient record; \*primary effectiveness outcome, all instruments that are administered at T3 and the CAM-ICU will be interpreted as secondary outcomes; † does not fit the description of an instrument, but is listed here for completeness; \*\*the expected effect refers to the comparison between control and intervention group. An up-pointing arrow connotes a reduced respective decline in the intervention group, it does not stand for more favourable values after surgery per se.

The first postoperative enquiry takes place (T1) within the first few days after surgery. At that point, delirium,<sup>53</sup> cognitive functioning,<sup>54-56</sup> physical strength,<sup>46,49</sup> and mobility<sup>47</sup> are assessed and information about somatic complications is extracted from the hospital’s electronic patient record (EPR). POD is screened for using the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) including modified Richmond Agitation and Sedation Scale (m-RASS) in the first five days following surgery according to guideline recommendations.<sup>61</sup> T2 and T3 take place one and six months after surgery respectively.

Short-term outcomes are duration of inpatient stay, and the occurrence of postoperative complications, including POD and mortality. PROMs and a brief neurocognitive assessment, evaluating patient’s postoperative cognitive abilities will be used as parameters to assessing long-term effects of the intervention, one and six months after surgery. PROMs are used to assess functional status, a proxy for frailty, health-related quality of life, and mental morbidity; the neurocognitive assessment focusses



1  
2  
3 on alertness, cognitive flexibility, and working memory. See *table 1* for instruments, operationalisation,  
4 time point of assessment and expected direction of effects.  
5  
6

7 The proposed intervention components affect either the pre- or the intraoperative phase. While all  
8 intervention components shall counteract POC and decline of autonomy one and six months after  
9 surgery, the specific measures focus on different aspects of postoperative health. Special attention is  
10 given to everyday functioning; including nutritional and fitness status, orientation, and somatic  
11 complications.  
12  
13

14 Malnourished patients will be provided with high-protein drinks for a maximum of 14 days up to the  
15 eve of their surgery day. Additionally, patients are offered a carbohydrate drink on the eve and two  
16 hours prior to surgery,<sup>62</sup> but also to reduce preoperative anxiety and discomfort.<sup>62,63</sup> Patients with  
17 frailty and poor physical fitness are prompted to undergo preoperative progressive strength and  
18 fitness training, instructed via a short personal introduction and information brochures and logged by  
19 a self-report diary. All patients are advised to perform breathing exercises, as taught by an information  
20 brochure.  
21  
22  
23  
24  
25  
26  
27

### 28 *Interventions*

29  
30  
31 Intervention components to reduce mental overload and prevent disorientation comprise the  
32 inclusion of relatives, extensive information giving about planned procedures, and the preservation of  
33 sensory orientation. The systematic inclusion of relatives or significant others in all procedures from  
34 the beginning of the inpatient stay onwards shall counteract potential disorientation within the  
35 unfamiliar, and potentially highly stressful setting. A detailed and comprehensible pre-operation  
36 counselling including information about the inpatient stay and the scheduled POC prevention  
37 measures shall serve as an additional orientation aid. Patients will be encouraged to bring personal  
38 items at admission, such as pillows, photographs, and music. This shall support recognition and  
39 diminish the risk of suffering POD. Furthermore, patients with need for vision aids, acoustic  
40 instruments, and dental prostheses are encouraged to retain these aids up to the anaesthetic induction  
41 to foster sensory orientation.  
42  
43  
44  
45  
46  
47  
48  
49

50 Measures to prevent somatic complications consist of screening and potential adjustment of  
51 potentially inadequate or multi-medication in accordance with national and international  
52 recommendations<sup>22,23</sup> and general refrainment from administering benzodiazepines. Patients with  
53 anaemia will be screened for iron deficiency. If an iron deficiency anaemia is diagnosed and the risk for  
54 intraoperative bleeding is estimated to be above 10%, patients will be supplemented with intravenous  
55 iron prior to surgery in accordance of the principles of Patient Blood Management.  
56  
57  
58  
59  
60

1  
2  
3 The proposed intraoperative measures shall prevent somatic complications and mental disorientation.  
4 The geriatric anaesthesia concept includes employing regional anaesthesia alone or in combination  
5 with general anaesthesia whenever possible to ensure an opioid-saving postoperative analgesia  
6 regime. When general anaesthesia is performed, BIS is used for neuromonitoring purposes. Further,  
7 certain medications will be avoided intraoperatively, in particular, benzodiazepines, atropine,  
8 anticholinergics, and central alpha-agonists. If muscle-relaxants are needed, short-acting substances  
9 are preferred as well as postoperative catheter-assisted analgesia. Thermal blankets from anaesthesia  
10 induction to post anaesthesia care will be given to the patient in order to avoid hypothermia.  
11  
12

13  
14  
15  
16  
17 During the implementation and intervention phases, training events by study staff and external experts  
18 will be performed at every affected hospital ward and in anaesthesia meetings. These meetings inform  
19 about relevant topics of in-patient care such as the preoperative administration of carbohydrate  
20 drinks, measures of POD prevention, patient information and adequate postoperative analgesia in the  
21 elderly. Anaesthetists are instructed to follow the comprehensive administration of BIS during surgery.  
22  
23

### 24 25 26 *Recruitment/sample size*

27  
28  
29 In this trial the sample size is motivated by having a reasonable amount of patients undergoing the  
30 intervention in order to descriptively and qualitatively describe if the intervention is feasible for being  
31 executed in the routine health care. Nevertheless with this sample size we will reach sufficient power  
32 for explanatorily identifying rare foreseen and unforeseen incidents, as suggested for feasibility  
33 trials.<sup>64,65</sup> The emergence of POCs depends on underlying conditions and type of surgery conducted. In  
34 the elected cohort, the likelihood of an occurrence of POCs is considerably above 10%,<sup>66,67</sup> so is the risk  
35 of losing the level of preoperative functioning and autonomy. A sample size of 30 is minimally required  
36 for the identification of an event with an average occurrence of 10% with a confidence of 95%.<sup>64</sup>  
37 Because of an expected dropout greater than 30%, as is common in studies that are performed under  
38 routine conditions, together with the plan to analyse multiple outcomes, we aim to recruit 80 patients  
39 in each of the three study arms, resulting in approximately 240 patients in total. The effect size of our  
40 intervention in our sample is not known as in its present combination it has not yet been tested.  
41 However, sufficiently powered effectiveness studies investigating similar populations to ours, aspects  
42 of our intervention, and/or on parts of the here assessed complications, came up with similar sample  
43 sizes.<sup>68,69</sup>  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53

### 54 55 56 *Data analysis*

57  
58 For the exploratory effectiveness of the intervention, a comparison between the control and the  
59 intervention group will be conducted. We plan to use the intention to treat (ITT) method to conduct  
60

the primary analyses. Missing values will be accounted for by using mixed modelling techniques. The data will be analysed using descriptive and inferential statistics. The effects of the intervention will be estimated by using segmented regressions.<sup>70-72</sup> For the effectiveness analyses, generalised two-level regression models (linear, logistic or Cox depending on the outcome) will be used. This enables a nuanced estimation of time- and intervention effects, taking into account time trends within- and between the groups. The first level connotes the progression of the individual patients and will be estimated in intercept and slope. The second level connotes the difference between persons, taking into account time and group-effects. Should the assumptions for segmented regressions be violated, the models will be adjusted accordingly. Propensity score methods will be used in case of strong violation.<sup>73</sup> Results with  $p < .05$  will be considered as statistically significant. As this study is of explorative nature, no adjustments will take place for multiple testing. However, the elevated risk of an occurrence of type-I errors will be regarded when interpreting the results.

## Feasibility assessment of the implementation

### *Procedures and instruments*

A process evaluation is conducted to explore the feasibility of the PeriAge intervention. The critical elements for capturing the degree of feasibility in this study are acceptance of those affected, in particular patients and clinical staff, as well as the, practicability, realisation and adoption, accessibility of the intervention, and fidelity to protocol, chosen by means of the current standards of feasibility studies (see table 2).<sup>74-76</sup>

Table 2. Quantitative and qualitative feasibility assessment; type and description of analysis.

Domain	Operationalisation	Quantitative analysis	Qualitative analysis <sup>***</sup>	
		Brief description	Staff	Patient
Acceptance	Satisfaction with the intervention and its implementation	--	x	x
Practicability	Relevance of the intervention and compatibility with the specific setting	(Effectiveness outcomes, see above)	x	x
Realisation and adoption	Realisation: intend and action to employ the intervention	- Data quality analysis on congruency, completeness, plausibility, and sources of potential errors. → reported and adapted if necessary	x	

	Adoption: adjusted execution of the intervention to fit the setting and recording of these adjustments	- descriptive statistics of self-report diary and intervention checklist	
Accessibility	Penetration of intervention and access for all designated and eligible recipients	Evaluation of reasons for non-participation, recruitment progression and attrition rate Analysis of demographics and morbidity of dropouts	x
Fidelity to protocol	Quality and of intervention delivery and adherence to implementation protocol	Evaluation of implementation processes and interim adaptations by intervention checklist records	x

\*\*\*Thematic analysis evaluation of semi-structured interviews

Using a mixed method approach, the feasibility evaluation is segmented into a quantitative and a qualitative analysis. The quantitative analysis consists of continuous documentation of the realisation of the intervention from the implementation phase onwards (see figure 2).

[FIGURE 2]

An intervention checklist is filled in for every patient. This checklist is tailored on risk factors and interventions of the study and enquires about the proper execution of individual interventions e.g. the reduction of inappropriate polypharmacy, the retainment of orientation aids and the usage of the BIS during surgery. With this collection of process data deviations from the protocol can be prevented, or alternatively, detected. Additional plausibility analyses of the outcome data are performed.

For the qualitative feasibility analyses, information on the experience of the clinical and study staff and patients regarding the individual intervention components are collected and evaluated. Firstly, meeting logs of the project will be described. Secondly, semi-structured interviews will be conducted examining experience and opinion of the interviewee about adequacy and purpose of the intervention, as well as impediments and facilitators of the implementation process. The interviews will contain mainly open-ended questions. Interviewing patients and professionals of different contexts shall capture different perspectives on the implementation and increase the validity of the results. While the patient interviews will be held within the intervention phase after completing the T3 enquiry, the staff interviews will be conducted twice; once during the implementation phase and once after the termination of the intervention phase. The first staff interview serves not only as an inspection of

1  
2  
3 feasibility, but also allows that necessary adjustments might be exposed and realised. The second  
4 interview repeats and finalises the inspection of feasibility.  
5  
6

### 7 *Recruitment/sample size*

8  
9 Additional to the recruitment of 240 patients for the effectiveness analysis, it is planned to interview  
10 5 to 10 study staff members medical assistants and clinicians, who are affected by the implementation.  
11 Additionally, seven randomly chosen patients of the intervention phase will be interviewed. These  
12 interviews take place after T3. The chosen sample size is based on experience and literature on  
13 saturation of information gain.<sup>77</sup>  
14  
15  
16  
17

### 18 *Data analysis*

19  
20 To perform the process evaluation, two structured analyses of the process- and outcome data will be  
21 performed on congruency and completeness in order to detect potential discrepancies between  
22 conception and realisations. The first analysis is conducted before initiation of the implementation  
23 phase and the second is conducted after the data collection is completed. The results of the  
24 evaluations as well as the results of the intervention checklist (see above), will be examined via  
25 descriptive statistics. The interviews will be recorded, transcribed and analysed by using a realist  
26 thematic analysis approach,<sup>78</sup> specifically a framework content analysis.<sup>79</sup> The thematic analysis  
27 approach is a method by which qualitative data is coded into themes (see figure 3). We will use a  
28 mainly deductive approach, as our feasibility outcomes are already pre-defined (see table 2). Coding  
29 schemes are developed beforehand and discussed regularly. Nevertheless, we are open to the  
30 possibility of inductive theme generation, if data suggests. The results will be reported using  
31 consolidated criteria for reporting qualitative research (COREQ).<sup>80</sup>  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42

43 [FIGURE 3]

44  
45 **Patient and public involvement** Patients and public were and will not be directly involved in the  
46 research study design. However, within the qualitative analysis, we will assess the patient's opinion of  
47 the PeriAge intervention, and about burden and time required to take part in this study. One research  
48 question is dedicated to obtain and integrate the patient's opinion into the results and eventually into  
49 the decision whether to continue and incorporate the programme in routine care. It is not planned to  
50 involve patients in the dissemination of the results. If the intervention shows to be feasible and brings  
51 added value into the healthcare of geriatric patients, it will be maintained and expanded to all wards  
52 and all surgical geriatric patients in the university medical centre Hamburg-Eppendorf.  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 **Software** Microsoft Access will be used for data collection, storage, and preparation. For most  
4 quantitative data analyses, it is anticipated to use the software R<sup>81</sup> and IBM SPSS Statistics<sup>82</sup>. Lastly, the  
5 software MAXQDA<sup>83</sup> will be used for qualitative data analyses.  
6  
7

## 8 9 **ETHICS AND DISSEMINATION**

10 **Ethical and safety considerations** The study will be carried out according to the Helsinki Declaration  
11 of the World Medical Association. The principles of good scientific practice will be followed. Study  
12 participation is voluntary and may be withdrawn at any moment. Written informed consent will be  
13 obtained prior to participation. Patients will be fully educated about the aims and procedure of the  
14 study, data collection and the use of collected data. The rejection of participation has no negative  
15 consequences for patients and their care. No foreseeable risk at any moment results from the  
16 participation in this study. No compassionate use will be carried out. All intervention components are  
17 non-invasive expect for the preoperative iron infusion if required according to the Patient Blood  
18 Management protocol. However, this is no experimental therapy method but an established and  
19 evidence-based measure, which is executed according to existing guidelines and approved by the  
20 local ethical review committee. Preserving principles of data sensitivity, data protection, and  
21 confidentiality requirements will be met. Significant deviations from the protocol, concerning  
22 recruitment, inclusion criteria, intervention, or statistical data analysis will be justified and discussed.  
23 Modifications and amendments will be listed in the appendices of the main publication. SPIRIT  
24 reporting guidelines have been used to write protocol.<sup>84</sup>  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36

37 **Dissemination plan** The results of the project will be published in scientific journals. In order to  
38 assure high accessibility, we aim to publish our work in open access journals, conditions permitting.  
39 Furthermore, the results will be presented at relevant national and international conferences.  
40 Additionally, a data basis shall be created that will help to inform clinical practice guidelines that  
41 enable and improve perioperative care and surgical outcomes of geriatric patients, respectively.  
42  
43  
44  
45

46 **Data deposition** The collected data will be deposited on a protected server of the University Medical  
47 Centre Hamburg-Eppendorf, with strongly regulated access even for study personnel. Due to  
48 substantial obstacles to de-identification (relatively small sample, routine care, a large amount of  
49 qualitative data, etc.), individual participant data will not be shared publicly. Researchers who submit  
50 a methodologically sound proposal to the principal investigator that is approved by the responsible  
51 review committee will be allowed to use data.  
52  
53  
54  
55  
56

## 57 **AUTHORS CONTRIBUTORS**

58  
59  
60

1  
2  
3 CO, MH, RK, and LK conceptualised the study, wrote the grant proposal, and obtained funding. LL,  
4 CO, AM, and LK designed the details of the study, with substantial contributions from MH and RK. RK  
5 is the responsible primary investigator of the project. LL and CO prepared the first draft of the  
6 manuscript. LP substantially contributed to implementing the individual interventions and the  
7 recruitment of patients. AEG and CZ, heads of the UKE Anaesthesiology department, supported and  
8 enabled the realisation of the study with their overall supervision. All authors contributed to critically  
9 revising the manuscript for important intellectual content, gave final approval of the version to be  
10 published, and agree to be accountable for the work as guarantors. The corresponding author attests  
11 that all listed authors meet authorship criteria and that no others meeting the criteria have been  
12 omitted.

13  
14  
15  
16  
17  
18  
19  
20  
21 **Funding** This work is funded by the Innovation Fund of the German Federal Joint Committee  
22 (Gemeinsamer Bundesausschuss), with the grant number 01VSF16057 (contact information: phone  
23 +49 30 27 58380, email: info@g-ba.de). The German Federal Joint Committee reviewed and  
24 approved the study design during the grant application process. It had no role in the conduct of the  
25 study and the publication process.

26  
27  
28  
29  
30 **Competing interests** None declared.

31  
32 **Patient consent** Not required.

33  
34  
35 **Ethics approval** Ethics Committee of the Medical Association Hamburg, Germany (study ID: PV5596).

36  
37 **Acknowledgements** G. Ketels and M. Lemke, both from the Department of Physiotherapy, UKE for the  
38 development and supervision of the prehabilitation-training program. R. Schulz, J. Janssen, and C.  
39 Raschke: for performing as models in the prehabilitation brochure. C. Langebrake from the UKE  
40 Pharmacy for the supervision of the PeriAge medication reconciliation. S. Bargel and G. Ohm from the  
41 UKE Developing department, for their support in submitting the grant proposal.

## 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

### REFERENCES

1. Fallpauschalenbezogene Krankenhausstatistik (DRG-Statistik), Diagnosen und Prozeduren der vollstationären Patientinnen und Patienten in Krankenhäusern Wiesbaden: Statistisches Bundesamt (Destatis); 2017 [17.08.2018]. Fachserie 12. Reihe 6.4:[Available from: <https://www.destatis.de/DE/Publikationen/Thematisch/Gesundheit/Krankenhaeuser/FallpauschalenKrankenhaus.html>].
2. Olotu-Steffen C, Gurlit S, Kiefmann R. Präoperative Vorbereitung und Evaluation: der ältere Patient. *Anästhesiol Intensivmed Notfallmed Schmerzther.* 2017;52(05):342-55.
3. Baquero GA, Rich MW. Perioperative care in older adults. *J Geriatr Cardiol.* 2015;12(5):465-9.
4. Deiner S, Westlake B, Dutton RP. Patterns of surgical care and complications in elderly adults. *J Am Geriatr Soc.* 2014;62(5):829-35.

- 1
  - 2
  - 3
  - 4
  - 5
  - 6
  - 7
  - 8
  - 9
  - 10
  - 11
  - 12
  - 13
  - 14
  - 15
  - 16
  - 17
  - 18
  - 19
  - 20
  - 21
  - 22
  - 23
  - 24
  - 25
  - 26
  - 27
  - 28
  - 29
  - 30
  - 31
  - 32
  - 33
  - 34
  - 35
  - 36
  - 37
  - 38
  - 39
  - 40
  - 41
  - 42
  - 43
  - 44
  - 45
  - 46
  - 47
  - 48
  - 49
  - 50
  - 51
  - 52
  - 53
  - 54
  - 55
  - 56
  - 57
  - 58
  - 59
  - 60
5. Lienhart A AY, Pequignot F Survey of anesthesia-related mortality in France. *Anesthesiology*. 2006;105:1087-97.
6. Sepehri A, Beggs T, Hassan A, et al. The impact of frailty on outcomes after cardiac surgery: a systematic review. *J Thorac Cardiovasc Surg*. 2014;148(6):3110-7.
7. Patel N, Minhas JS, Chung EM. Risk Factors Associated with Cognitive Decline after Cardiac Surgery: A Systematic Review. *Cardiovasc Psychiatry Neurol*. 2015;2015:370612.
8. Rundshagen I. Postoperative cognitive dysfunction. *Dtsch Arztebl Int*. 2014;111(8):119-25.
9. Kim S, Brooks AK, Groban L. Preoperative assessment of the older surgical patient: honing in on geriatric syndromes. *Clin Interv Aging*. 2015;10:13-27.
10. Carlisle JB. Pre-operative co-morbidity and postoperative survival in the elderly: beyond one lunar orbit. *Anaesthesia*. 2014;69 Suppl 1:17-25.
11. Newman MF, Kirchner JL, Phillips-Bute B, et al. Longitudinal assessment of neurocognitive function after coronary-artery bypass surgery. *N Engl J Med*. 2001;344(6):395-402.
12. Scandrett KG, Zuckerbraun BS, Peitzman AB. Operative risk stratification in the older adult. *Surg Clin North Am*. 2015;95(1):149-72.
13. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. *J Gerontol A Biol Sci Med Sci*. 2001;56(3):M146-56.
14. Beggs T, Sepehri A, Szwajcer A, et al. Frailty and perioperative outcomes: a narrative review. *Can J Anaesth*. 2015;62(2):143-57.
15. Aunan JR, Watson MM, Hagland HR, et al. Molecular and biological hallmarks of ageing. *Br J Surg*. 2016;103(2):e29-46.
16. DAS-Taskforce, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften. S3 Leitlinie Analgesie, Sedierung und Delirmanagement in der Intensivmedizin (DAS-Leitlinie 2015): GMS Ger Med Sci; 2015 [Available from: <https://www.egms.de/static/de/journals/gms/2015-13/000223.shtml>].
17. Bauer JM, Volkert D, Wirth R, et al. Diagnostik der Mangelernährung des älteren Menschen. *Dtsch Med Wochenschr*. 2006;131(5):223-7.
18. Weimann A, Braga M, Harsanyi L, et al. ESPEN Guidelines on Enteral Nutrition: Surgery including organ transplantation. *Clin Nutr*. 2006;25(2):224-44.
19. Jack S, West M, Grocott MP. Perioperative exercise training in elderly subjects. *Best Pract Res Clin Anaesthesiol*. 2011;25(3):461-72.
20. Deutz NE, Bauer JM, Barazzoni R, et al. Protein intake and exercise for optimal muscle function with aging: recommendations from the ESPEN Expert Group. *Clin Nutr*. 2014;33(6):929-36.
21. Mohanty S, Rosenthal RA, Russell MM, et al. Optimal Perioperative Management of the Geriatric Patient: A Best Practices Guideline from the American College of Surgeons NSQIP and the American Geriatrics Society. *J Am Coll Surg*. 2016;222(5):930-47.
22. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. *J Am Geriatr Soc*. 2015;63(11):2227-46.
23. Holt S, Schmiedl S, Thurmann PA. Potentially inappropriate medications in the elderly: the PRISCUS list. *Dtsch Arztebl Int*. 2010;107(31-32):543-51.
24. Smith I, Kranke P, Murat I, et al. Perioperative fasting in adults and children: guidelines from the European Society of Anaesthesiology. *Eur J Anaesthesiol*. 2011;28(8):556-69.
25. Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin e.V. and Berufsverband Deutscher Anästhesisten e.V. Entschlüsseungen, Empfehlungen, Vereinbarungen. Ebelsbach: Aktiv Druck & Verlag GmbH; 2011.
26. Ali Abdelhamid Y, Chapman MJ, Deane AM. Peri-operative nutrition. *Anaesthesia*. 2016;71 Suppl 1:9-18.
27. Broadbent E, Petrie JK, Alley GP, et al. Psychological Stress Impairs Early Wound Repair Following Surgery. *Psychosom Med*. 2003;65(5):865-9.
28. Wozniak SE, Coleman J, Katlic MR. Optimal Preoperative Evaluation and Perioperative Care of the Geriatric Patient: A Surgeon's Perspective. *Anesthesiol Clin*. 2015;33(3):481-9.



- 1
- 2
- 3 29. Inouye SK, Bogardus ST, Jr., Baker DI, et al. The Hospital Elder Life Program: a model of care
- 4 to prevent cognitive and functional decline in older hospitalized patients. *Hospital Elder Life*
- 5 *Program. J Am Geriatr Soc.* 2000;48(12):1697-706.
- 6
- 7 30. Munoz M, Acheson AG, Auerbach M, et al. International consensus statement on the peri-
- 8 operative management of anaemia and iron deficiency. *Anaesthesia.* 2017;72(2):233-47.
- 9
- 10 31. Mehra T, Seifert B, Bravo-Reiter S, et al. Implementation of a patient blood management
- 11 monitoring and feedback program significantly reduces transfusions and costs. *Transfusion.*
- 12 2015;55(12):2807-15.
- 13
- 14 32. Association of Anaesthetists of Great Britain and Ireland. Peri-operative care of the elderly
- 15 2014. *Anaesthesia.* 2014;69:81-98.
- 16
- 17 33. Gombotz H, Zacharowski K, Spahn DR, et al. Patient Blood Management. Stuttgart, New York:
- 18 Georg Thieme Verlag; 2013. Available from: [https://www.thieme-](https://www.thieme-connect.de/products/ebooks/book/10.1055/b-002-59191)
- 19 [connect.de/products/ebooks/book/10.1055/b-002-59191](https://www.thieme-connect.de/products/ebooks/book/10.1055/b-002-59191).
- 20
- 21 34. Radtke FM, Franck M, Lendner J, et al. Monitoring depth of anaesthesia in a randomized trial
- 22 decreases the rate of postoperative delirium but not postoperative cognitive dysfunction. *Br*
- 23 *J Anaesth.* 2013;110 Suppl 1:i98-105.
- 24
- 25 35. Vaurio LE, Sands LP, Wang Y, et al. Postoperative delirium: the importance of pain and pain
- 26 management. *Anesth Analg.* 2006;102(4):1267-73.
- 27
- 28 36. Rundshagen I. Anästhesiologische Strategien bei Hochbetagten. *Anästhesie und*
- 29 *Intensivmedizin.* 2015;56:534-45.
- 30
- 31 37. Varadhan KK, Neal KR, Dejong CH, et al. The enhanced recovery after surgery (ERAS) pathway
- 32 for patients undergoing major elective open colorectal surgery: a meta-analysis of
- 33 randomized controlled trials. *Clin Nutr.* 2010;29(4):434-40.
- 34
- 35 38. Santa Mina D, Clarke H, Ritvo P, et al. Effect of total-body prehabilitation on postoperative
- 36 outcomes: a systematic review and meta-analysis. *Physiotherapy.* 2014;100(3):196-207.
- 37
- 38 39. Rubin FH, Williams JT, Lescisin DA, et al. Replicating the Hospital Elder Life Program in a
- 39 community hospital and demonstrating effectiveness using quality improvement
- 40 methodology. *J Am Geriatr Soc.* 2006;54(6):969-74.
- 41
- 42 40. Damschroder LJ, Aron DC, Keith RE, et al. Fostering implementation of health services
- 43 research findings into practice: a consolidated framework for advancing implementation
- 44 science. *Implement Sci.* 2009;4:50.
- 45
- 46 41. Partridge JS, Harari D, Martin FC, et al. The impact of pre-operative comprehensive geriatric
- 47 assessment on postoperative outcomes in older patients undergoing scheduled surgery: a
- 48 systematic review. *Anaesthesia.* 2014;69 Suppl 1:8-16.
- 49
- 50 42. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental
- 51 activities of daily living. *Gerontologist.* 1969;9(3):179-86.
- 52
- 53 43. Moore GF, Audrey S, Barker M, et al. Process evaluation of complex interventions: Medical
- 54 Research Council guidance. *Bmj.* 2015;350:h1258.
- 55
- 56 44. Melnyk M, Casey RG, Black P, et al. Enhanced recovery after surgery (ERAS) protocols: Time
- 57 to change practice? *Canadian Urological Association journal = Journal de l'Association des*
- 58 *urologues du Canada.* 2011;5(5):342-8.
- 59
- 60 45. Zemke J. Erfassung der Sozialen Situation (SoS) nach Nikolaus. *GGP - Geriatrie und*
- Gerontologische Pflege.* 2018;02(06):260-2.
46. Millor N, Lecumberri P, Gomez M, et al. Gait Velocity and Chair Sit-Stand-Sit Performance
- Improves Current Frailty-Status Identification. *IEEE Trans Neural Syst Rehabil Eng.* 2017.
47. Bohannon RW. Sit-to-stand test for measuring performance of lower extremity muscles.
- Percept Mot Skills.* 1995;80(1):163-6.
48. Podsiadlo D, Richardson S. The timed "Up & Go": a test of basic functional mobility for frail
- elderly persons. *J Am Geriatr Soc.* 1991;39(2):142-8.
49. Phillips P. Grip strength, mental performance and nutritional status as indicators of mortality
- risk among female geriatric patients. *Age Ageing.* 1986;15(1):53-6.

- 1
  - 2
  - 3
  - 4
  - 5
  - 6
  - 7
  - 8
  - 9
  - 10
  - 11
  - 12
  - 13
  - 14
  - 15
  - 16
  - 17
  - 18
  - 19
  - 20
  - 21
  - 22
  - 23
  - 24
  - 25
  - 26
  - 27
  - 28
  - 29
  - 30
  - 31
  - 32
  - 33
  - 34
  - 35
  - 36
  - 37
  - 38
  - 39
  - 40
  - 41
  - 42
  - 43
  - 44
  - 45
  - 46
  - 47
  - 48
  - 49
  - 50
  - 51
  - 52
  - 53
  - 54
  - 55
  - 56
  - 57
  - 58
  - 59
  - 60
50. Dapp U, Anders J, von Renteln-Kruse W, et al. The longitudinal urban cohort ageing study (LUCAS): study protocol and participation in the first decade. *BMC Geriatr.* 2012;12(1):35.
51. Skates J, Anthony P. Identifying Geriatric Malnutrition in Nursing Practice: The Mini Nutritional Assessment (MNA<sup>®</sup>)—An Evidence-Based Screening Tool. *J Gerontol Nurs.* 2012;38(3):18-27.
52. Ely EW, Margolin R, Francis J, et al. Evaluation of delirium in critically ill patients: validation of the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU). *Crit Care Med.* 2001;29(7):1370-9.
53. Kalbe E, Kessler J, Calabrese P, et al. DemTect: a new, sensitive cognitive screening test to support the diagnosis of mild cognitive impairment and early dementia. *Int J Geriatr Psychiatry.* 2004;19(2):136-43.
54. Zimmermann P, Fimm B. A test battery for attentional performance. *Applied neuropsychology of attention*: Psychology Press; 2004. p. 124-65.
55. Reitan RM, Wolfson D. Conventional intelligence measurements and neuropsychological concepts of adaptive abilities. *J Clin Psychol.* 1992;48(4):521-9.
56. Ware JE, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: Construction of Scales and Preliminary Tests of Reliability and Validity. *Med Care.* 1996;34(3):220-33.
57. Bullinger M, Kirchberger J. Der SF-36-Fragebogen zum Gesundheitszustand. *Hogrefe Verlag, Göttingen.* 1998:65–72.
58. Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression screening scale: a preliminary report. *J Psychiatr Res.* 1982;17(1):37-49.
59. Spitzer RL, Kroenke K, Williams JB, et al. A brief measure for assessing generalized anxiety disorder: the GAD-7. *Arch Intern Med.* 2006;166(10):1092-7.
60. Le Manach Y, Collins G, Rodseth R, et al. Preoperative Score to Predict Postoperative Mortality (POSPOM) Derivation and Validation. *Anesthesiology.* 2016;124(3):570-9.
61. Aldecoa C, Bettelli G, Bilotta F, et al. European Society of Anaesthesiology evidence-based and consensus-based guideline on postoperative delirium. *Eur J Anaesthesiol.* 2017;34(4):192-214.
62. Smith MD, McCall J, Plank L, et al. Preoperative carbohydrate treatment for enhancing recovery after elective surgery. *Cochrane Database Syst Rev.* 2014(8):CD009161.
63. Kaška M, Grosmanová Tá, Havel E, et al. The impact and safety of preoperative oral or intravenous carbohydrate administration versus fasting in colorectal surgery – a randomized controlled trial. *Wien Klin Wochenschr.* 2010;122(1):23-30.
64. Viechtbauer W, Smits L, Kotz D, et al. A simple formula for the calculation of sample size in pilot studies. *J Clin Epidemiol.* 2015;68(11):1375-9.
65. Billingham SAM, Whitehead AL, Julious SA. An audit of sample sizes for pilot and feasibility trials being undertaken in the United Kingdom registered in the United Kingdom Clinical Research Network database. *BMC Medical Research Methodology.* 2013;13:104-.
66. Story DA. Postoperative complications in elderly patients and their significance for long-term prognosis. *Curr Opin Anaesthesiol.* 2008;21(3):375-9.
67. McNicol L, Story DA, Leslie K, et al. Postoperative complications and mortality in older patients having non-cardiac surgery at three Melbourne teaching hospitals. *Med J Aust.* 2007;186(9):447-52.
68. Ommundsen N, Wyller TB, Nesbakken A, et al. Preoperative geriatric assessment and tailored interventions in frail older patients with colorectal cancer: a randomized controlled trial. *Colorectal Dis.* 2018;20(1):16-25.
69. Deschodt M, Braes T, Broos P, et al. Effect of an Inpatient Geriatric Consultation Team on Functional Outcome, Mortality, Institutionalization, and Readmission Rate in Older Adults with Hip Fracture: A Controlled Trial. *J Am Geriatr Soc.* 2011;59(7):1299-308.
70. Wagner AK, Soumerai SB, Zhang F, et al. Segmented regression analysis of interrupted time series studies in medication use research. *J Clin Pharm Ther.* 2002;27(4):299-309.

- 1
- 2
- 3 71. Gebski V, Ellingson K, Edwards J, et al. Modelling interrupted time series to evaluate
- 4 prevention and control of infection in healthcare. *Epidemiol Infect.* 2012;140(12):2131-41.
- 5 72. Kontopantelis E, Doran T, Springate DA, et al. Regression based quasi-experimental approach
- 6 when randomisation is not an option: interrupted time series analysis. *Bmj.* 2015;350:h2750.
- 7 73. Rosenbaum PR RD. The central role of the propensity score in observational studies for
- 8 causal effects. *Biometrika.* 1983;70:41-55.
- 9 74. Craig P, Dieppe P, Macintyre S, et al. Developing and evaluating complex interventions: the
- 10 new Medical Research Council guidance. *Bmj.* 2008;337:a1655.
- 11 75. Glasgow RE, McKay HG, Piette JD, et al. The RE-AIM framework for evaluating interventions:
- 12 what can it tell us about approaches to chronic illness management? *Patient Educ Couns.*
- 13 2001;44(2):119-27.
- 14 76. Proctor E, Silmere H, Raghavan R, et al. Outcomes for implementation research: conceptual
- 15 distinctions, measurement challenges, and research agenda. *Adm Policy Ment Health.*
- 16 2011;38.
- 17 77. Marshall MN. Sampling for qualitative research. *Fam Pract.* 1996;13(6):522-5.
- 18 78. Braun V, Clarke V. Using thematic analysis in psychology. *Qual Res Psychol.* 2006;3(2):77-101.
- 19 79. Gale NK, Heath G, Cameron E, et al. Using the framework method for the analysis of
- 20 qualitative data in multi-disciplinary health research. *BMC Med Res Methodol.*
- 21 2013;13(1):117.
- 22 80. Tong A, Craig J, Sainsbury P. Consolidated criteria for reporting qualitative research (COREQ):
- 23 a 32-item checklist for interviews and focus groups. *Int J Qual Health Care.* 2007;19(6):349-
- 24 57.
- 25 81. R Core Team. R: A language and environment for statistical computing. R Foundation for
- 26 Statistical Computing. Vienna, Austria. URL <http://www.R-project.org/>.2013.
- 27 82. IBM Corp. Released 2017. IBM SPSS Statistics for Windows VA, NY: IBM Corp.
- 28 83. VERBI S. MAXQDA 2018 [computer software]. Berlin, Germany: VERBI Software. Available
- 29 from <https://www.maxqda.com2017>.
- 30 84. Chan A-W, Tetzlaff JM, Gøtzsche PC, et al. SPIRIT 2013 explanation and elaboration: guidance
- 31 for protocols of clinical trials. *Bmj.* 2013;346:e7586.
- 32
- 33
- 34
- 35
- 36
- 37

### SUPPLEMENTARY FIGURE LEGENDS

**Figure 1 Sequential study design.** Allocation randomisation is not feasible, due to the risk of contamination or cross over between groups. During the control and implementation phase, the intervention components will be developed, the implementation planned and gradually introduced. In the intervention phase, the exhaustive intervention will be applied. The enquiry period, entailing recruitment and follow up of all phases, will be realised within 18 months.

**Figure 2 Incorporation of the implementation and feasibility assessment within the study outline.** From the implementation phase onwards up to the completion of the intervention phase, the quantitative and qualitative feasibility analyses will be performed.

**Figure 3 Scheme of theme coding of qualitative feasibility interviews.** Potential statements of patients and staff are coded into the different organising aspects of the global feasibility theme.




Figure 1 Sequential study design. Allocation randomisation is not feasible, due to the risk of contamination or cross over between groups. During the control and implementation phase, the intervention components will be developed, the implementation planned and gradually introduced. In the intervention phase, the exhaustive intervention will be applied. The enquiry period, entailing recruitment and follow up of all phases, will be realised within 18 months.

89x69mm (300 x 300 DPI)




Figure 2 Incorporation of the implementation and feasibility assessment within the study outline. From the implementation phase onwards up to the completion of the intervention phase, the quantitative and qualitative feasibility analyses will be performed.

89x54mm (300 x 300 DPI)




Figure 3 Scheme of theme coding of qualitative feasibility interviews. Potential statements of patients and staff are coded into the different organising aspects of the global feasibility theme.

89x62mm (300 x 300 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

# Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

## Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin J, Doré C, Parulekar W, Summerskill W, Groves T, Schulz K, Sox H, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. *Ann Intern Med.* 2013;158(3):200-207

			Page Number
<b>Administrative information</b>			
Title	<a href="#">#1</a>	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	<a href="#">#2a</a>	Trial identifier and registry name. If not yet registered, name of intended registry	2
Trial registration: data set	<a href="#">#2b</a>	All items from the World Health Organization Trial Registration Data Set	2
Protocol version	<a href="#">#3</a>	Date and version identifier	1
Funding	<a href="#">#4</a>	Sources and types of financial, material, and other support	13
Roles and responsibilities: contributorship	<a href="#">#5a</a>	Names, affiliations, and roles of protocol contributors	1, 13

1	Roles and	<a href="#">#5b</a>	Name and contact information for the trial sponsor	13
2	responsibilities: sponsor			
3	contact information			
4				
5				
6	Roles and	<a href="#">#5c</a>	Role of study sponsor and funders, if any, in study design; collection, management,	13
7	responsibilities: sponsor		analysis, and interpretation of data; writing of the report; and the decision to submit the	
8	and funder		report for publication, including whether they will have ultimate authority over any of	
9			these activities	
10				
11				
12				
13	Roles and	<a href="#">#5d</a>	Composition, roles, and responsibilities of the coordinating centre, steering committee,	13
14	responsibilities:		endpoint adjudication committee, data management team, and other individuals or	
15	committees		groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	
16				
17				
18				
19	<b>Introduction</b>			
20				
21	Background and	<a href="#">#6a</a>	Description of research question and justification for undertaking the trial, including	3-4
22	rationale		summary of relevant studies (published and unpublished) examining benefits and harms	
23			for each intervention	
24				
25				
26	Background and	<a href="#">#6b</a>	Explanation for choice of comparators	4
27	rationale: choice of			
28	comparators			
29				
30				
31				
32	Objectives	<a href="#">#7</a>	Specific objectives or hypotheses	4
33				
34	Trial design	<a href="#">#8</a>	Description of trial design including type of trial (eg, parallel group, crossover, factorial,	5
35			single group), allocation ratio, and framework (eg, superiority, equivalence, non-	
36			inferiority, exploratory)	
37				
38				
39				
40	<b>Methods: Participants,</b>			
41	<b>interventions, and</b>			
42	<b>outcomes</b>			
43				
44				
45	Study setting	<a href="#">#9</a>	Description of study settings (eg, community clinic, academic hospital) and list of	5
46			countries where data will be collected. Reference to where list of study sites can be	
47			obtained	
48				
49				
50				
51	Eligibility criteria	<a href="#">#10</a>	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for	5
52			study centres and individuals who will perform the interventions (eg, surgeons,	
53			psychotherapists)	
54				
55				
56	Interventions:	<a href="#">#11a</a>	Interventions for each group with sufficient detail to allow replication, including how	8
57	description		and when they will be administered	
58				
59				
60				



1	Interventions:	<a href="#">#11b</a>	Criteria for discontinuing or modifying allocated interventions for a given trial	9
2	modifications		participant (eg, drug dose change in response to harms, participant request, or improving	
3			/ worsening disease)	
4				
5				
6	Interventions: adherence	<a href="#">#11c</a>	Strategies to improve adherence to intervention protocols, and any procedures for	9
7			monitoring adherence (eg, drug tablet return; laboratory tests)	
8				
9				
10	Interventions:	<a href="#">#11d</a>	Relevant concomitant care and interventions that are permitted or prohibited during the	n/a
11	concomitant care		trial	
12				
13				
14	Outcomes	<a href="#">#12</a>	Primary, secondary, and other outcomes, including the specific measurement variable	6,7,10
15			(eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time	
16			to event), method of aggregation (eg, median, proportion), and time point for each	
17			outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is	
18			strongly recommended	
19				
20				
21				
22	Participant timeline	<a href="#">#13</a>	Time schedule of enrolment, interventions (including any run-ins and washouts),	6
23			assessments, and visits for participants. A schematic diagram is highly recommended	
24			(see Figure)	
25				
26				
27				
28	Sample size	<a href="#">#14</a>	Estimated number of participants needed to achieve study objectives and how it was	6
29			determined, including clinical and statistical assumptions supporting any sample size	
30			calculations	
31				
32				
33	Recruitment	<a href="#">#15</a>	Strategies for achieving adequate participant enrolment to reach target sample size	9,11
34				
35				
36	<b>Methods: Assignment</b>			
37	<b>of interventions (for</b>			
38	<b>controlled trials)</b>			
39				
40				
41	Allocation: sequence	<a href="#">#16a</a>	Method of generating the allocation sequence (eg, computer-generated random	5
42	generation		numbers), and list of any factors for stratification. To reduce predictability of a random	
43			sequence, details of any planned restriction (eg, blocking) should be provided in a	
44			separate document that is unavailable to those who enrol participants or assign	
45			interventions	
46				
47				
48				
49				
50	Allocation concealment	<a href="#">#16b</a>	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially	5
51	mechanism		numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until	
52			interventions are assigned	
53				
54				
55	Allocation:	<a href="#">#16c</a>	Who will generate the allocation sequence, who will enrol participants, and who will	5
56	implementation		assign participants to interventions	
57				
58				
59				
60				

1	Blinding (masking)	<a href="#">#17a</a>	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	n/a
2				
3				
4	Blinding (masking):	<a href="#">#17b</a>	If blinded, circumstances under which unblinding is permissible, and procedure for	n/a
5	emergency unblinding		revealing a participant's allocated intervention during the trial	
6				
7				
8	<b>Methods: Data</b>			
9	<b>collection,</b>			
10	<b>management, and</b>			
11	<b>analysis</b>			
12				
13				
14				
15	Data collection plan	<a href="#">#18a</a>	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	7-8,10-11
16				
17				
18				
19				
20				
21				
22				
23				
24	Data collection plan:	<a href="#">#18b</a>	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	9,11
25	retention			
26				
27				
28				
29				
30	Data management	<a href="#">#19</a>	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	9,11
31				
32				
33				
34				
35	Statistics: outcomes	<a href="#">#20a</a>	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	9,11
36				
37				
38				
39	Statistics: additional	<a href="#">#20b</a>	Methods for any additional analyses (eg, subgroup and adjusted analyses)	9,11
40	analyses			
41				
42				
43	Statistics: analysis	<a href="#">#20c</a>	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	9,11
44	population and missing			
45	data			
46				
47				
48	<b>Methods: Monitoring</b>			
49				
50				
51	Data monitoring: formal	<a href="#">#21a</a>	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	n/a
52	committee			
53				
54				
55				
56				
57				
58				
59				
60				

1	Data monitoring: interim	<a href="#">#21b</a>	Description of any interim analyses and stopping guidelines, including who will have	n/a
2	analysis		access to these interim results and make the final decision to terminate the trial	
3				
4				
5	Harms	<a href="#">#22</a>	Plans for collecting, assessing, reporting, and managing solicited and spontaneously	12
6			reported adverse events and other unintended effects of trial interventions or trial	
7			conduct	
8				
9				
10	Auditing	<a href="#">#23</a>	Frequency and procedures for auditing trial conduct, if any, and whether the process will	n/a
11			be independent from investigators and the sponsor	
12				
13				
14	<b>Ethics and</b>			
15	<b>dissemination</b>			
16				
17				
18	Research ethics approval	<a href="#">#24</a>	Plans for seeking research ethics committee / institutional review board (REC / IRB)	12
19			approval	
20				
21				
22	Protocol amendments	<a href="#">#25</a>	Plans for communicating important protocol modifications (eg, changes to eligibility	12
23			criteria, outcomes, analyses) to relevant parties (eg, investigators, REC / IRBs, trial	
24			participants, trial registries, journals, regulators)	
25				
26				
27	Consent or assent	<a href="#">#26a</a>	Who will obtain informed consent or assent from potential trial participants or	12
28			authorised surrogates, and how (see Item 32)	
29				
30				
31	Consent or assent:	<a href="#">#26b</a>	Additional consent provisions for collection and use of participant data and biological	n/a
32	ancillary studies		specimens in ancillary studies, if applicable	
33				
34				
35	Confidentiality	<a href="#">#27</a>	How personal information about potential and enrolled participants will be collected,	12
36			shared, and maintained in order to protect confidentiality before, during, and after the	
37			trial	
38				
39				
40				
41	Declaration of interests	<a href="#">#28</a>	Financial and other competing interests for principal investigators for the overall trial	13
42			and each study site	
43				
44				
45	Data access	<a href="#">#29</a>	Statement of who will have access to the final trial dataset, and disclosure of contractual	12-13
46			agreements that limit such access for investigators	
47				
48	Ancillary and post trial	<a href="#">#30</a>	Provisions, if any, for ancillary and post-trial care, and for compensation to those who	n/a
49	care		suffer harm from trial participation	
50				
51				
52	Dissemination policy:	<a href="#">#31a</a>	Plans for investigators and sponsor to communicate trial results to participants,	12
53	trial results		healthcare professionals, the public, and other relevant groups (eg, via publication,	
54			reporting in results databases, or other data sharing arrangements), including any	
55			publication restrictions	
56				
57				
58				
59				
60				

1	Dissemination policy:	<a href="#">#31b</a>	Authorship eligibility guidelines and any intended use of professional writers	13
2	authorship			
3				
4				
5	Dissemination policy:	<a href="#">#31c</a>	Plans, if any, for granting public access to the full protocol, participant-level dataset, and	12
6	reproducible research		statistical code	
7				

## Appendices

11	Informed consent	<a href="#">#32</a>	Model consent form and other related documentation given to participants and	n/a
12	materials		authorised surrogates	
13				
14				
15	Biological specimens	<a href="#">#33</a>	Plans for collection, laboratory evaluation, and storage of biological specimens for	n/a
16			genetic or molecular analysis in the current trial and for future use in ancillary studies, if	
17			applicable	
18				
19				

The SPIRIT checklist is distributed under the terms of the Creative Commons Attribution License CC-BY-ND 3.0. This checklist was completed on 15. May 2019 using <https://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)

### Reasons for n/a:

### Interventions: concomitant care:

as this study is conducted under routine care conditions, all concomitant care is permitted for all patients at all times.

### Data monitoring: formal committee:

This is a pilot study, including a process evaluation in which data is monitored as part of the outcome.

### Data monitoring: interim analysis:

No interim analysis of the effectiveness subsection of the study is done. Data quality (consistence and completeness) is checked for 6 months into recruitment as part of the process evaluation.

### Auditing:

In this pilot study no auditing planned. However in the course of the process evaluation, internal auditing is planned to reveal flaws and deficiencies.

### Consent or assent: ancillary studies:

No ancillary studies planned, no biological specimens used.

### Ancillary and post trial care:

No ancillary studies planned, no post-trial care and no harm in this study.

### Biological specimens:

None used

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only